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‘There is more here than meets the eyes.’ 
Murasaki Shikibu 
  
  
  
ABSTRACT 
Optic nerve hypoplasia (ONH) is a congenital ocular malformation with a thin optic nerve in 
one or both eyes. ONH has been associated with neurodevelopmental disorders and pituitary 
dysfunction, but the prevalence of these comorbidities are still unknown, especially in 
children with less severe visual impairment and unilateral disease. The aims of this thesis 
were to examine the prevalence of ONH in children, to determine the prevalence of 
intellectual disability, autism spectrum disorder, motor impairment, and pituitary dysfunction 
in unilateral and bilateral disease, as well as to identify genetic variants underlying ONH. 
Methods: In study I, a population-based cohort of patients with ONH was established 
including patients who were diagnosed with ONH, below 20 years of age, and living in 
Stockholm in December 2009. Ophthalmological assessments were performed, and the Five 
to Fifteen parent questionnaire (FTF) was used to screen for developmental problems. 
Subsequently, study II and study III were population-based cross-sectional cohort studies. In 
study II, neurodevelopmental disorders were confirmed by the FTF, neurological 
assessments, reviewing previous neuropsychological investigations, or conducting 
neuropsychological tests. In study III, motor impairments were assessed using a specific 
protocol and previous neuroradiology was reviewed. Blood sampling was performed to 
screen for pituitary dysfunction together with analysis of growth curves and medical history. 
Study IV included 29 patients with ONH who were analysed with array comparative genomic 
hybridization followed by whole genome sequencing and in silico filtering of single 
nucleotide variants in 42 candidate genes. Rare variants were verified by Sanger sequencing. 
Results: The prevalence of ONH in children in Stockholm was 17.3/100 000. Unilateral 
ONH was almost as common as bilateral (45%). Intellectual disability was more common in 
bilateral ONH than in unilateral ONH (56% vs 9%, p< 0.001). Autism spectrum disorders 
were diagnosed in 17%, without correlation to laterality. Motor impairments were identified 
in 47% of the patients and were significantly more prevalent in bilateral ONH. In contrast, 
pituitary hormone deficiency (PHD) was confirmed in 29% of the cohort and 19% had 
multiple PHD, without correlation to laterality. Furthermore, presence of structural pituitary 
abnormalities had a very high sensitivity for PHD. Finally, we identified three rare variants in 
COL4A1 and three rare variants in COL4A2, of which two were assessed as likely 
pathogenic. In addition, we found an interesting rare variant in OPA1 and two other likely 
pathogenic variants in SOX5 and PAX6. 
Conclusions: ONH is a common ocular malformation in children, with a prevalence of 
17.3/100 000 in Stockholm. Unilateral ONH seems to be as common as bilateral. Children 
with both unilateral and bilateral ONH have a high risk of neurodevelopmental disorders and 
PHD, but bilateral ONH increases the risk of intellectual disability, motor impairment, and 
brain abnormalities. These findings need to be considered when designing screening, care, 
and follow-up programs. Our genetic study suggests that a genetic cause of ONH is more 
common than previously reported and highlights COL4A1 and COL4A2 as candidate genes. 
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1 INTRODUCTION 
Optic nerve hypoplasia (ONH) is a congenital ocular malformation with a thin optic nerve 
with a reduced number of retinal ganglion cell axons, resulting in a visual outcome from near 
normal to blindness. It is one of the most common causes of visual impairment in children in 
developed countries and often occurs in association with neurodevelopmental disorders and 
hormone deficiencies. The prevalence of these comorbidities are still unknown, especially in 
children with less severe visual impairment and unilateral ONH. 
1.1 HISTORY 
The first reported patient with ONH was a child with a small and pale optic disc, nystagmus, 
and blindness, described by Magnus in 1884.1 The first illustration of ONH was by Schwarz 
in 1915,2 and in 1941,  Reeves published the first association of ONH and absent septum 
pellucidum.3 However, this association was later incorrectly ascribed to George de Morsier, 
who described two patients with absent septum pellucidum, where the first patient had a 
unilateral vertically rotated optic tract without any history of visual impairment, and the 
second had a visual field defect with enlargement of the blind spot suggesting a defect optic 
disc. From the literature, de Morsier supplemented these two patients with eight other patients 
with absent septum pellucidum and other ophthalmological disorders.4 The only patient 
included with ONH was the one Reeves had discovered.5 De Morsier associated optic nerve 
or ocular malformations with agenesis of the septum pellucidum and postulated the term ‘la 
dysplasie septo-optique’.4  
Later in 1970, Ellenberger and Runyan published the first case with unilateral ONH, absent 
septum pellucidum, and dwarfism.6 The same year Hoyt et al described nine additional 
patients with ONH and pituitary dwarfism, and made the important association between ONH 
and growth hormone deficiency (GHD).7 Four of these patients also had an absent septum 
pellucidum and Hoyt et al described it as ‘septo-optic dysplasia’ (SOD), referring to de 
Morsier. SOD is sometimes called de Morsier syndrome although it is not known if he ever 
identified a case of ONH.5 
1.2 PREVALENCE OF OPTIC NERVE HYPOPLASIA 
ONH is the most common optic nerve malformation8 and one of the most frequent causes of 
visual impairment and blindness in children in developed countries.9-12 In Swedish children 
with visual impairment, only cerebral visual impairment and non-hereditary optic atrophy 
were more common, and ONH was followed by retinopathy of prematurity as a causative 
factor in a study from 1997.9 The prevalence of children with ONH has been reported to be 
increasing, partly due to increased awareness of the condition and improved diagnostics 
among ophthalmologists, but it may also represent a true increase.13 According to the 
Swedish Register of Visually Impaired Children, i.e. with a best-corrected visual acuity 
(BCVA) of < 0.3, approximately seven children per 100 000 had ONH causing visual 
impairment, and the prevalence had significantly increased from 1980 to 1999.13, 14 In 
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Northwest England, the prevalence of ONH/SOD was reported to be 10.9/100 000 in children 
younger than 16 years of age in 2006.15 However, Patel et al concluded that the prevalence 
was likely underestimated due to lack of patients with ONH and mild visual impairment, and 
they did not report the proportion of unilateral and bilateral ONH.15 Many other studies have 
included only patients with bilateral ONH or had a high proportion of bilateral ONH. For 
instance, in a large prospective study, 82% of the children had bilateral ONH.16 Men and 
females have been reported to be equally affected by ONH.9, 17 
1.3 AETIOLOGY 
1.3.1 Embryology 
1.3.1.1 Development of the optic nerve 
The aetiology of ONH is in the majority of cases unknown, but is considered to be 
multifactorial with a combination of environmental factors and genetic vulnerability. The 
association with pituitary dysfunction and other brain malformations makes it important to 
understand the underlying embryology. The optic nerves, the anterior and posterior pituitary 
lobes, the hypothalamus, and the forebrain develop from the anterior neural plate.18 The 
cranial neuropore closes on day 24 and the forebrain develops into the telencephalon 
(primordia of the cerebral hemispheres) and the diencephalon. During the early fourth fetal 
week, the optic vesicles, which are the primordia of the retinas and optic nerves, appear on 
each side of the diencephalon and remain attached to the brain via the optic stalks.19 The optic 
vesicle evaginates towards the surface ectoderm (the future lens placode) and thereafter 
invaginates to become the optic cup (Figure 1). The inner layer of the optic cup develops into 
the neural retina, and the outer layer give rise to the retinal pigment epithelium (Figure 2). At 
the posterior pole of the optic cup is the optic nerve head, which is connected to the optic 
stalk. The first retinal ganglion cells (RGCs) appear in the sixth fetal week in the central 
retina, close to the optic nerve head, and later differentiated RGCs develop in more peripheral 
retinal regions. Consequently, later generated RGC axons have a longer distance to travel into 
the optic nerve and by the eighth week a solid optic nerve (cranial nerve II) is present.20 
Remarkably, over three million RGC axons must be guided to each optic nerve, and RGC 
neurogenesis is limited in time.19-21 
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How the axon guidance is performed is not fully understood, but cadherins seem to be 
important in the axonogenesis of RGCs, and inhibitory chondroitin sulfate might prevent 
axonal growth in wrong direction. Furthermore, slit molecules are known to influence the 
growth cone, and within the retina they attract the RGC axons, but at the optic chiasm they 
work repulsive. This is explained by a mechanism where different molecules at the growth 
cone modulate the response. Another important strategy for the axon guidance is when later 
generated RGC axons find and fasciculate with earlier generated axons, which have already 
reached the optic nerve head.19 Furthermore, the expression of sonic hedgehog (Shh) in RGCs 
has, in a mouse model, been shown to be important in order to extend the axons to the optic 
nerve.23 The axons in the retinal nerve fiber layer are organized in the papillomacular bundle, 
the superior and inferior arcuate bundles, and the nasal bundle. 
RGC axons in the dorsal retina are helped by the dorsal-ventral gradient of Eph and ephrin 
molecules. This explains why mutations in EPH receptor B2 (Ephb2) and Ephb3 give rise to 
superior segmental ONH.19 In this condition, there is a defect in the superior (dorsal) 
quadrant of the retina, resulting in an inferior visual field defect, but visual acuity is normal. 
In addition, there is an association between patients with superior segmental ONH and 
mothers with type 1 diabetes mellitus, indicating that metabolic pathways play a role in axon 
guidance.24, 25  
RGC axons exit the eye through the optic disc. To pass the final exit from the retina to the 
optic nerve there is a netrin-dependent regulation for the RGC axons. Netrin-1 is an axon 
guidance molecule that binds to the DCC netrin 1 receptor (DCC), which is expressed by the 
RGC axons. Netrin-1 mutant mice have ONH, which is also seen in animals without DCC 
function.26 Interestingly, the absence of netrin-1 and DCC may also result in dysgenesis of 
corpus callosum and hypothalamus.19  
Another gene associated with ONH, corpus callosum dysgenesis, and pituitary dysplasia is 
the transcription factor gene HESX homeobox 1 (HESX1). Many target genes for HESX1 are 
unknown, but probably include genes affecting axon guidance and cell migration.19 HESX1 
works like a functional antagonist to the transcription factor PROP paired-like homeobox 1 
(PROP1), which is also of importance in the pituitary organogenesis. HESX1 mutations have 
been reported to create an inability to inhibit the activity of PROP1.27, 28 
The growth of axons continues into the second trimester, and programmed apoptosis regulate 
the refinement of the connections throughout gestation. At the time of birth, approximately 
1.2 million axons populate each optic nerve.29 The optic nerves form the optic chiasm, where 
approximately half of the fibers cross over to the contralateral optic tract (decussation of 
medial fibers). The RGC axons form synapses in the suprachiasmatic nucleus of the 
hypothalamus, the superior colliculus and the pretectum in the midbrain, but the main relay 
between the retina and the visual cortex is the dorsal lateral geniculate nucleus in the 
thalamus (Figure 3). From there, the following optic radiation ends up in the visual cortex in 
the occipital lobe. Thereby, the visual pathway extends throughout the entire brain. 
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which responds to signals from the neurons in the hypothalamus. These neurons connect the 
hypothalamus to the pituitary gland through the pituitary stalk, or infundibulum. Several 
transcription factors are involved in both hypothalamic and retinal development.34 
1.3.2 Genetics 
Although most cases of ONH are sporadic, there are also familial cases suggesting a genetic 
aetiology.35-37 Mouse models and studies of familial cases have identified a number of genes 
relevant to the occurrence of ONH. Subsequently, ONH and SOD in humans have previously 
been associated with mutations in several developmental transcription factor genes; HESX1, 
SRY (sex determining region y)-box 2 (SOX2), SOX3, and orthodenticle homeobox 2 
(OTX2), albeit in low frequency.32, 36, 38, 39 Both point mutations, as well as gene dose 
variation have been described.32, 39, 40 
The first homozygous mutation in HESX1 in humans was described in two siblings with 
ONH, corpus callosum agenesis, absent septum pellucidum, and an ectopic neurohypophysis 
with panhypopituitarism.36 Despite this interesting finding, the frequency of HESX1 
mutations in a large cohort of patients with SOD was less than 1%.41 Until 2012, only five 
ONH patients with HESX1 mutation had been described.5 Still, this seems to be the gene 
which is most often analysed in children with ONH. 
Furthermore, the transcription factors SOX2 and SOX3 are dose-dependent regulators of the 
sonic hedgehog transcription, and mouse embryos lacking the signaling protein sonic 
hedgehog have been reported to have severe ONH and pituitary hypoplasia.33 In addition, 
mutations in the X-linked gene encoding calcium/calmodulin-dependent serine protein kinase 
(CASK) have been associated with brain malformations and ONH in humans.42 Similarly, 
mutations in collagen type IV alpha 1 chain (COL4A1) have been associated with 
porencephaly, schizencephaly, cerebrovascular disease, and ophthalmological disorders 
including at least one patient with ONH.43, 44 Moreover, it has been suggested that mutations 
in the OPA1 gene, connected to optic atrophy 1, may underlay some cases of ONH.45 In 
summary, there are an increasing number of single case-reports of mutations in different 
developmental genes, and besides X-linked inheritance, both autosomal dominant and 
autosomal recessive inheritance have been described. 
ONH has also been associated with different syndromes, e.g. cardio-facio-cutaneous 
syndrome46, Noonan syndrome47, and trisomy 13.17 An overlap in symptomatology with 
Kallmann syndrome (idiopathic hypogonadotropic hypogonadism and anosmia/hyposmia) 
has led to the detection of prokineticin receptor 2 (PROKR2) mutations in two patients with 
ONH.48 
In conclusion, mutations in different genes have been described in only a minority of cases 
with ONH. However, due to the increasing rate of genetic testing of affected individuals, 
several developmental genes have been proposed as candidate genes for ONH.32, 49 
Nevertheless, except for the study of McNay et al,41 there has not been any genetic cohort 
study of ONH. Subsequently, it is unknown to what extent genetic aetiologies contribute to 
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ONH and few patients with ONH are offered genetic testing. Further genetic studies would 
help us to better understand the development of the visual pathways, the connection to 
hypothalamus and pituitary abnormalities, and brain development. 
1.3.3 Prenatal risk factors 
Several ONH studies have reported young maternal age and primiparity as predominant 
maternal features.14, 50-52 Patel et al reported a higher prevalence of ONH in urban areas with 
high population densities and speculated that predisposing aetiological factors such as 
environmental or lifestyle factors may be linked to deprivation.15 In another cohort study, 
there was a high prevalence of prenatal maternal weight loss or poor weight gain, indicating 
an important role of nutrition.52  
Furthermore, ONH has long been associated with alcohol and drug abuse, and in a Swedish 
study of 30 children with fetal alcohol syndrome (FAS), ONH was found in 48% of the 
eyes.53 In addition, Ribeiro et al reported ONH in 25% of the eyes in Portuguese children 
with FAS.54 The causality is supported by a recent animal study that showed that prenatal 
ethanol exposure cause ONH by selective inhibition of sonic hedgehog signaling in retinal 
progenitor cells, resulting in failure to extend axons to the optic nerve.23 The study strongly 
indicates that the timing of exposure during fetal development is essential for the 
phenotype.23  
Other suggested aetiological factors are prenatal exposure to prescription drugs (e.g. 
anticonvulsants, antidepressants), maternal smoking, viral infections (e.g. congenital 
cytomegalovirus infection), and maternal diabetes.14, 31, 51 However, these prenatal exposures 
were not significantly increased in the large cohort study of Garcia-Filion et al.52 These 
authors have suggested that future research should focus on the significance of young 
maternal age, primiparity, prenatal nutrition, maternal weight gain, and other factors of 
deprivation.55 Recently, ONH has been described in infants with prenatal Zika virus infection 
and microcephaly, emphasizing the risk of ONH in certain congenital infections.56, 57 
Another hypothesis is that ONH is a result of a vascular destructive lesion,58, 59 and it has 
been speculated that early gestational bleeding as well as use of vasoconstrictors (e.g. 
tobacco, cocaine) may increase the risk of a vascular insult.60 Interestingly, increased 
prevalence of gestational vaginal bleeding (33%) has been reported from a larger cohort study 
of children with ONH.52 
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24% of the patients were blind and 43% had severe visual impairment (visual acuity < 0.3).31 
Moreover, different patterns of visual field defects have been reported.75 
ONH is a non-progressive disease, and in fact, the visual acuity may improve during the first 
four years of life, because of myelinisation and visual maturation.76 
1.5 HYPOTHALAMIC AND PITUITARY DYSFUNCTION 
1.5.1 Hypopituitarism 
Since 1970, ONH has been associated with hypopituitarism.6, 7 The main hypothesis is that a 
dysfunctional hypothalamus fails to orchestrate the pituitary gland,77 but there may also be 
defects of the pituitary infundibulum or the pituitary gland itself.78 Hypopituitarism or 
pituitary hormone deficiency (PHD) is the lack of one pituitary hormone or several 
hormones, i.e. multiple PHD. GHD is considered to be the most common PHD in ONH, 
followed by central hypothyroidism. Deficiency in adrenocorticotropic hormone (ACTH) 
impairs the function of the adrenal glands and leads to deficiency of corticosteroids. Cortisol 
deficiency can induce hypoglycemia and may be life-threatening in combination with stress. 
Dysfunction of gonodotropins (follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH)) can result in either precocious or late puberty.77, 79 Furthermore, the water balance is 
disturbed when there is a deficiency of antidiuretic hormone, and may give rise to central 
diabetes insipidus. Hyperprolactinemia is common in ONH, and is explained by dysfunction 
of the dopaminergic inhibition from hypothalamus.16, 77 
1.5.2 Prevalence of hypopituitarism 
The prevalence of hypopituitarism in unilateral and bilateral ONH is still unknown despite 
many studies, and ranges from 28% to 72% depending on study design and population.79-82 
This is likely explained by an underrepresentation of children with unilateral ONH and milder 
disease in most studies. In a prospective study, including 87% bilateral ONH, 
endocrinopathies were described in 69% of the children with ONH.81 GHD was reported as 
the most common PHD (68%), followed by central hypothyroidism (44%), ACTH deficiency 
(31%), and diabetes insipidus (11%).81 In another cross-sectional study of 101 children with 
ONH (71% bilateral ONH), patients with bilateral ONH had a significant greater risk of PHD 
than unilateral ONH (35% and 10%, respectively).80 This is in contrast to the study of Ahmad 
et al, who reported that hormone deficiencies were not associated with laterality of ONH.66 
To further complicate the picture, the hormonal dysfunction may be congenital or develop 
over time, and there is an uncertainty regarding how often late-onset hormonal dysfunction 
evolve, which has been shown for GHD, central hypothyroidism, ACTH deficiency, and 
diabetes insipidus.83, 84 In addition, puberty disturbances are not well investigated. In a 
retrospective study, Oatman et al found two patients with precocious puberty (2/101, 2%) and 
4/8 (50%) patients had gonadotropin deficiency.79  
Population-based studies are needed to establish the prevalence of PHD and to conclude 
whether children with unilateral ONH or a structural normal pituitary have a less pronounced 
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risk of hypopituitarism. Unilateral ONH seems to be a milder disease, and these children may 
benefit from a less extensive monitoring program as well as information of a more positive 
prognosis.  
1.5.3 Septo-optic dysplasia 
Historically, the absence of septum pellucidum has been given an important clinical 
significance in determining the risk of PHD. However, many studies contradicts this theory,30, 
66, 77, 80, 81 and several researchers advocate abandoning the term since it has repeatedly been 
shown that an absent septum pellucidum does not increase the risk of hypopituitarism. Still 
the concept of SOD is commonly used in the clinic and in research. SOD is defined by any 
combination of ONH, midline neuroradiological abnormalities (including corpus callosum 
agenesis and absent septum pellucidum), and pituitary hypoplasia/hypopituitarism.32 The 
broad inclusion criteria of SOD mean that a patient with SOD does not always have ONH. 
Consequently, it can be difficult to compare studies of SOD patients with ONH studies. 
1.5.4 Structural pituitary abnormalities 
In ONH, radiological findings of structural pituitary abnormalities have been reported to be 
highly predictive of PHD, but there is an ongoing debate regarding the negative predictive 
value of a normal pituitary gland on MRI for exclusion of PHD in children with ONH.80, 81 
This is an important clinical question, whether all children with ONH should have a thorough 
endocrinologically follow-up, or if those with a normal pituitary gland should be offered a 
less meticulous follow-up, or none at all. 
Ramakrishnaiah et al have published a cross-sectional study of 101 children with ONH, 
showing that neurohypophyseal abnormalities (including absent pituitary infundibulum, 
ectopic posterior pituitary bright spot, and absent posterior pituitary bright spot) on MRI had 
a sensitivity of 96% for PHD and a specificity of 92% for normal pituitary function.80 On the 
contrary, both Oatman et al and Garcia-Filion et al concluded from two large studies that a 
structurally normal pituitary is a poor predictor of normal pituitary function, and does not 
exclude hormonal dysfunction in children with ONH.79, 81 This debate is ongoing. 
1.5.5 Hypothalamic dysfunction 
Hyperprolactinemia has been suggested to be a marker of hypothalamic dysfunction in 
children with ONH, due to reduced dopaminergic tone.78 However, more recent findings 
challenge its role as a reliable prognosticator of pituitary dysfunction.85 Other symptoms of 
hypothalamic dysfunction in ONH are hyperphagia and obesity, hypophagia, body 
temperature dysregulation, water-seeking behaviour, and abnormal sleep-wake cycles.51, 86 
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1.6 NEUROLOGICAL DYSFUNCTION 
1.6.1 Neurodevelopmental disorders 
Neurodevelopmental disorders are reported to be common in children with ONH. In 1984, 
Margalith et al described 51 children with ONH in a population-based study, including 92% 
with bilateral disease. Seventy-one percent had mental retardation, 57% cerebral palsy, 37% 
epilepsy, and 20% behavioural problems. The behavioural problems included attention deficit 
disorder, aggressive, or autistic behaviour.50 
Another study of 93 children with ONH identified developmental delay in 46% of the group 
with bilateral ONH, poor vision and nystagmus, but normal development in all 11 children 
with unilateral ONH.74 The authors concluded that an eye examination could predict the risk 
of developmental disorders.74 Significantly more difficulties were reported from a prospective 
study which included 18% unilateral ONH and demonstrated developmental delay in 39% of 
children with unilateral ONH and 78% in bilateral disease.16 However, being a selected 
cohort from a referral center in USA, there is a risk of selection bias and the prevalence may 
be overestimated. Still, they showed that bilateral ONH increased the risk of development 
delay, as did corpus callosum hypoplasia and hypothyroidism.16 
In general, blind children have been reported to have a higher risk of autism spectrum 
disorders (ASD),87 but few studies have focused on the risk of ASD in children with ONH. 
Two smaller Swedish studies of visually impaired children with bilateral ONH reported ASD 
in 29% (8/28) and 69% (9/13), respectively.88, 89 A third study described ASD in 31% of a 
cohort with 83 children with bilateral ONH and profound or severe visual impairment.90 
There is a paucity of data concerning less severe and unilateral ONH. 
1.6.2 Neurological impairment 
The prevalence of motor impairments in children with ONH is unknown. Fahnehjelm et al 
identified hypotonia, dyskinesia, or motor delay in 21% (6/28) in a selected cohort with 
bilateral ONH and severe visual impairment,88 and Signorini et al described a high degree of 
motor clumsiness in a retrospective study.91 In addition, several studies have reported cases of 
cerebral palsy and epilepsy.31, 50, 88, 91-94 For exemple, Margalith et al described epilepsy in 
37% of a selective cohort with 92% bilateral ONH and 57% had cerebral palsy,50 and 
Fahnehjelm et al found epilepsy in 21% of a subgroup of patients with bilateral ONH and 
severe visual impairment.88 Nevertheless, population-based studies, including patients with 
less severe visual impairment and unilateral disease, are needed to understand the risk of 
motor impairment, cerebral palsy, and epilepsy in children with ONH. 
1.6.3 Brain malformations 
As mentioned earlier, ONH is closely associated with several brain malformations. The most 
commonly reported are absence of septum pellucidum, corpus callosum agenesis, and 
pituitary abnormalities, but also more rare conditions such as schizencephaly, porencephaly, 
and hydrocephalus have been reported (Figure 6).30, 50, 74, 80, 95 Furthermore, Hellström et al 
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2 AIMS OF THE THESIS 
2.1 GENERAL AIMS 
The general aims of the thesis were to examine the prevalence of ONH in children and to 
determine the prevalence of neurodevelopmental disorders, motor impairments, and pituitary 
dysfunction in unilateral and bilateral disease. In addition, the aim was to identify novel genes 
relevant to ONH and in as many children as possible to identify a genetic cause. 
2.1.1 Study I 
The aims were to report the prevalence of unilateral and bilateral ONH, ocular characteristics 
and coexisting behavioural problems in children with ONH in Stockholm, Sweden. The 
hypotheses were that ONH is more prevalent and the proportion of unilateral ONH is higher 
than previously reported. We also hypothesized that behavioural problems are more common 
in bilateral disease. 
2.1.2 Study II 
The aim was to examine the prevalence of intellectual disability and ASD in patients with 
unilateral and bilateral ONH. Our hypotheses were that these problems would be common, 
but that unilateral disease would be associated with a less pronounced risk. 
2.1.3 Study III 
The aims were to describe the prevalence of neurological and hormonal dysfunction in a 
population-based cohort of patients with ONH, comparing unilateral and bilateral disease. 
Furthermore, the aims were to identify structural brain abnormalities and investigate whether 
these could be used prognostically. We hypothesized that patients with unilateral ONH would 
have a lower risk of neurological and pituitary dysfunction. 
2.1.4 Study IV 
The last study aimed to identify genetic variants underlying ONH in a well-characterised 
cohort of patients with ONH. The hypothesis was that genetic causes are more common than 
previously reported.
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3 METHODOLOGICAL CONSIDERATIONS 
In this chapter, the methods used in the four studies will be summarized, and strengths and 
weaknesses will be discussed. 
3.1 POPULATION-BASED COHORT 
The foundation of the four studies is a population-based cross-sectional cohort of children 
and adolescents with ONH, who were below 20 years of age and living in the county of 
Stockholm in December 2009. The database at the St. Erik Eye hospital was searched for 
diagnosed optic disc malformations (Q14.2, Q14.8) and SOD (Q0.44), according to the 
International Classification of Diseases, Tenth Revision (ICD-10). The consultants at Astrid 
Lindgren Children’s Hospital were asked to report the same conditions. Since the St. Erik 
Eye hospital is the only department of paediatric ophthalmology in Stockholm along with a 
consultant neuropaediatric eye department at Astrid Lindgren Children’s Hospital, we were 
able to identify all the children and adolescents with a diagnosis of ONH in our region. 
Altogether, 176 children and adolescents with optic nerve malformations were detected.  
After excluding patients with other optic disc malformations than ONH, patients from other 
counties, and patients who had been incorrectly diagnosed, 79 patients with ONH were 
identified. Letters of invitation were sent out for enrolment together with information about 
the study and request for informed consent to all 79 patients. Of these, 53 families accepted 
clinical assessments and another 12 families gave permission to review the medical records 
and previous neuropsychological investigations. In addition, one family accepted review of 
the ophthalmological medical record. Five families declined to participate, and eight families 
were not reached despite a second letter and repeated phone calls. However, these 13 patients 
were included in the prevalence study of ONH. On the other hand, the estimate of ONH 
prevalence was based on children below 18 years of age, and therefore, three older patients 
were excluded from the prevalence study, leaving 76 patients instead of 79 (Figure 7). In 
study II and III, 65 patients were included, accounting for 82% of the eligible cases (Figure 
7).  
This is a unique population-based cohort of patients with ONH from the rather large county 
of Stockholm with a population of 2.1 million (Statistics Sweden 2010). Although we believe 
we were able to detect all children and adolescents with a diagnosis of ONH in the region, 
mild and asymptomatic cases may have been missed. However, a search for asymptomatic 
cases in the general population would require an extremely large study sample, which was 
not feasible. 
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A study limitation is that it was not possible to obtain fundus photographs from all the 
patients because of poor cooperation or poor quality of the photographs (e.g. due to 
nystagmus). On the other hand, this study supports that the simple manual Zeki method is 
reliable and valuable in diagnosing ONH. 
3.2.2 Best-corrected visual acuity 
The patients underwent clinical assessment of BCVA using methods suitable for the age and 
capacity; the Teller acuity cards (Precision Vision, Woodstock, IL, USA),98 Lea symbols 
(LEA-Test Ltd, Helsinki, Finland),99 HVOT test,100 and Konstatin Moutakis chart (Ortho 
KM, Lund, Sweden).100 BCVA was classified according to the World Health Organization 
(WHO) as blindness (0 - < 0.05), severe visual impairment (0.05 - < 0.1), moderate visual 
impairment (0.1 - < 0.3), or mild or no visual impairment (≥ 0.3). In study I and II, BCVA 
was described and analysed as decimal acuity, but in study III, BCVA was supplemented and 
converted to logMAR (minimal angle of resolution) values (-0.2 to 1.5; decline with better 
visual acuity) in patients with BCVA ≥ 0.05 to be able to use a continuous variable in the 
analysis of neurological impairment. The BCVA from the totally blind patients are not 
represented on test charts and could not be described as either decimal BCVA or logMAR. In 
order to include the blind patients in the analysis of the correlation between BCVA and 
comorbidities, we categorized the patients in different groups according to the WHO’s 
classification.  
3.2.3 Other ophthalomological assessments including visual fields 
The patients’ intraocular pressures were assessed with a non-contact tonometry (Topcon CT-
80 Computerized Tonometer, Japan) or a rebound tonometer, the Icare.101 The presence of 
strabismus was tested and the refraction was assessed in cycloplegia. In addition, visual field 
examinations were performed if the patient could cooperate. Computerized Rarebit technique 
has been shown to be suitable for assessment of children from six years of age and was used 
to examine the 30 degree visual fields.102, 103 The test consists of presentations of one or two 
high-contrast light spots (microdots) briefly presented against a dark background on a liquid 
crystal display screen. The patient responds with the corresponding single or double click on 
the mouse. The results are presented as the overall mean hit rate, and a hit rate ≥ 90% and < 5 
depressed locations (out of 30 test areas) were used as the limit for normal visual field 
results.104, 105 
A limitation is that Rarebit visual fields could be performed in only 16 patients in one or both 
eyes (in total, 24 eyes). Nevertheless, all these examinations, except for one, gave reliable 
results. 
3.3 NEUROPSYCHOLOGICAL ASSESSMENTS 
3.3.1 The Five to Fifteen parent questionnaire 
In both study I and II, we used the Five to Fifteen parent questionnaire (FTF) to screen for 
developmental problems. The questionnaire was sent to the parents before the clinical 
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assessment and was collected during the visit. The FTF is a validated tool for assessing 
general development and behaviour in children five to 15 years of age.106-108 The 
questionnaire consists of 181 items representing eight domains: motor skills, executive 
functions, perception, memory, language, learning, social skills, and emotional/behavioural 
problems. Each statement can be answered as either: does not apply (score of zero), applies 
sometimes or to some extent (score of one), or definitely applies (score of two). The mean 
domain scores were calculated and compared with normative data for the relevant age 
group.106, 107 A score of at least the 90th percentile is indicative of definite developmental 
problems and a score of at least the 98th percentile indicates major developmental problems.  
In study I, the FTF was used to provide an overview of the type and severity of 
developmental problems in children and adolescents with ONH. The eight domains are 
usually presented separately, but in study I, we made an attempt to combine the domains to 
be able to compare developmental problems between patients with unilateral and bilateral 
ONH. Therefore, also each domain was given a score of zero, one, or two, indicating that the 
domain result was below the 90th percentile, above the 90th percentile, or above the 98th 
percentile, respectively. Subsequently, the maximum total domain score was 8x2= 16. 
This model made it possible to compare the median total domain scores (range 0-16) between 
unilateral and bilateral ONH, and there was a statistically significant difference, indicating 
that patients with bilateral ONH have more developmental problems. Nevertheless, this 
model has been criticized for not being validated, and in study II, we strictly followed the 
FTF manual.  
In study II, the FTF was used to exclude intellectual disability and ASD in patients who had 
not had a neuropsychiatric assessment. In these patients, normal intelligence was defined as a 
normal neurological assessment, ordinary schooling, and a Five to Fifteen learning mean 
domain score below the 90th percentile (this domain is only validated for children from the 
age of nine). In the same way, ASD was excluded in patients with normal neurological 
assessment, ordinary schooling, and a Five to Fifteen social skill mean domain score below 
the 90th percentile. In study II, we only used the FTF for children between five to 15 years of 
age, and to calculate a mean domain score, more than 50% of the items within the domain 
needed to be answered. Borderline cases may have been missed, but the FTF has a high 
sensitivity for intellectual disability and ASD.108 Nevertheless, the FTF is not validated for 
testing visually impaired children and was only used to exclude intellectual disability or ASD 
in patients with BCVA ≥ 0.3.  
The FTF is a comprehensive questionnaire and to answer all the 181 items is time consuming. 
In total, forty-eight families returned the questionnaire, and after exclusion of patients 
younger or older than five to fifteen years of age and incomplete questionnaires, 34 
questionnaires remained. The results from the learning and social skill domains were used in 
study II if other neuropsychological assessment was absent. A drawback from using the FTF 
is that some parents of children with severe developmental problems returned incomplete 
questionnaires. Some parents also commented that these questions were not relevant to their 
 21 
 
child, and probably they were not motivated to fill in the lack of skills, which is 
understandable. This could have been improved if the parents received assistance while 
filling in the questionnaire. However, most families answered all the items and contributed to 
the data on developmental problems in patients with ONH. 
3.3.2 Wechsler Intelligence Scales 
In study II, we retrieved and re-evaluated previous neuropsychological investigations. 
Patients who had not been tested previously were tested by a psychologist with the Wechsler 
Intelligence Scale for Children, Fourth Edition (WISC-IV),109 or if they were older than 18 
years of age, the Wechsler Adult Intelligence Scale, Fourth Edition.110 The results were 
analysed with regard to the four indices: verbal comprehension, perceptual reasoning, 
freedom from distractibility, and processing speed, as well as for full scale intelligence 
quotient (FSIQ). The FSIQ is based on a mean of 100 and standard deviation of 15 and is 
derived from a combination of 10 core subtests. It is considered to be the most representative 
estimate of global intellectual functioning. The mean index scores and mean FSIQ scores, 
namely the mean composite scores, were compared between the patients with unilateral and 
bilateral ONH and correlated to BCVA. Intellectual disability was defined as an IQ of less 
than 70 combined with deficits in adaptive functioning. 
An advantage of using the Wechsler Scales is that we could report the prevalence of 
intellectual disability rather than the wider concept of developmental delay reported 
previously.16 Intellectual disability is by definition a dysfunctional condition that needs to be 
identified. The Wechsler scales are validated, have normative data, and are well-established 
both in the clinic and in research to evaluate global intellectual functioning. However, as with 
most neuropsychological methods, they are not validated for visually impaired individuals. 
Consequently, in children with severe visual impairment or blindness, neuropsychological 
tests, such as the Wechsler Scales, need modifications and various complementary tests are 
often used.111 In study II, patients with severe visual impairment or blindness had previously 
been assessed with different neuropsychological methods in different combinations, and a 
skilled psychologist, experienced in testing visually impaired children, re-evaluated every 
neuropsychological investigation to ensure that the diagnosis of intellectual disability had 
been correctly made. Still, it is a study limitation that the patients were examined using 
different neuropsychological tests. Within the study, one patient with BCVA < 0.1 was tested 
with WISC-IV. Due to blindness she could not participate in the subtests for perceptual 
reasoning and processing speed, but performed so well in the other subtests that she was 
considered to have above average intelligence (but could not get a FSIQ-score).  
3.3.3 Autism assessment 
Patients who fulfilled several criteria for ASD (Figure 8) or attention deficit hyperactivity 
disorder (ADHD) according to the Diagnostic and Statistical Manual of Mental Disorders 
(DSM), Fifth Edition,112 were referred for further investigations. A diagnosis of ASD or 
ADHD was established in cases where thorough neuropsychiatric assessment revealed 
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symptoms fulfilling DSM-V112 or the previous Fourth Edition113 criteria for ADHD or ASD, 
with the latter including autistic disorder, Asperger’s disorder, and pervasive developmental 
disorder not otherwise specified. Patients with merely autistic traits were not included as 
having ASD. In patients who were not neuropsychologically investigated and had BCVA ≥ 
0.3, we used the FTF to exclude ASD when the social skill mean domain score was below the 
90th percentile, and the neurological assessment was normal, as well as ordinary schooling. 
A weakness of the study design is that no standardized autism assessment was conducted. 
However, there is a lack of reliable testing instruments for ASD in visually impaired children. 
Promising efforts have been made to modify the Autism Diagnostic Observation Schedule 
(ADOS) and the Autism Diagnostic Interview, Revised (ADI-R),114 but these need to be 
validated further. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Diagnostic criteria for autism spectrum disorder (ASD) simplified from DSM-5.112 
Diagnostic criteria for autism spectrum disorder (ASD)  
An individual must meet criteria A, B, C, D, and E. 
A. Persistent deficits in social communication and social interaction across multiple contexts, 
as manifested by the following, currently or by history: 
1. Deficits in social-emotional reciprocity, ranging, for example, from abnormal social 
approach and failure of normal back-and-forth conversation; to reduced sharing of 
interest, emotions, or affect; to failure to initiate or respond to social interactions. 
2. Deficits in nonverbal communicative behaviours used for social interaction, ranging, for 
example, from poorly integrated verbal and nonverbal communication; to abnormalities in 
eye contact and body language or deficits in understandning and use of gestures; to a 
total lack of facial expressions and nonverbal communication. 
3. Deficits in developing, maintaining, and understanding relationships, ranging, for 
example, from difficulties adjusting behaviour to suit various social contexts; to difficulties 
in sharing imaginative play or in making friends; to absence of interest in peers. 
 
B. Restricted, repetitive patterns of behaviour, interests, or activities, as manifested by at least 
two of the following, currently or by history: 
1. Stereotyped or repetitive motor movements, use of objects, or speech. 
2. Insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal 
or nonverbal behaviour. 
3. Highly restricted, fixated interests that are abnormal in intensity or focus. 
4. Hyper- or hyporeactivity to sensory input or unusual interests in sensory aspects of the 
environment. 
 
C. Symptoms must be present in the early developmental period (but may not become fully 
manifest until social demand exceed limited capacities, or may be masked by learned 
strategies in later life). 
 
D. Symptoms cause clinically significant impairment in social, occupational, or other important 
areas of current functioning. 
 
E. These disturbances are not better explained by intellectual disability or global developmental 
delay. Intellectual disability and ASD frequently co-occur; to make comorbid diagnoses of 
ASD and intellectual disability, social communication should be below that expected for 
general developmental level. 
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3.4 NEUROLOGICAL ASSESSMENT 
A structured neurological assessment was conducted by a paediatrician, blinded to the 
patient’s clinical characteristics. The protocol was based on motor function tests that 
distinguish children with deficits in motor control115, 116 adjusted for a visually impaired 
population. The protocol included gross motor function tests (walking on heels, the Fog test, 
standing on one leg for 20 seconds, jumping on one leg 20 times, and alternating jumps) and 
fine motor function tests (pencil grip, drawing a person, threading beads, finger opposition 
test, and diadochokinesis for 10 seconds), as well as reflexes, muscle tone, head 
circumference, speech, and contact. To be assessed as pathological, the gross and fine motor 
function domains required two findings of marked motor abnormalities. Children younger 
than six years of age were examined according to the Swedish screening form used at the 
Child Health Centers including developmental assessment and neurological examination.117 
Hand preference was determined based on observation during the assessment and asked for. 
The parents and children/adolescents were also interviewed regarding the medical history. 
After the visit, data on other diagnoses (e.g. cerebral palsy and epilepsy) and results from 
neuroradiology were collected from medical records.  
Although this is the first study which have neurologically examined and presented prevalence 
of motor impairment in patients with ONH, it is a study weakness that the neurological 
protocol we used was only partly validated. It was designed for study III, building on the 
work of Touwen,118 Gillberg,115 and Landgren et al.116 Furthermore, the analysis of the results 
was in agreement with Hadders-Algra’s book ‘The Neurological Examination of the Child 
with Minor Motor Neurological Dysfunction’.119  
We did not have a proper control group, but before the final decision if a patient had ONH or 
not, nine patients with other optic nerve malformations were also examined according to the 
neurological protocol, and could be considered a small control group regarding motor 
impairments. None of the nine children in the control group had impairments in gross or fine 
motor function. Their median age at neurological assessment was 11.5 years (range 5.6-15.8 
years) and was similar to the ONH patients’, but logMAR value was median 0.0 (range -0.2-
0.19) and all the patients had only mild or no visual impairment, in contrast to the ONH 
cohort. In this small control group, three patients had optic nerve coloboma, two had morning 
glory syndrome, two had optic pits, one had other optic disc anomaly, and one patient was 
misdiagnosed and had normal optic discs. The finding that no neurological impairments were 
identified in the small control group indicates that the neurological protocol at least did not 
overestimate motor impairments. In addition, the motor impairments identified with the 
neurological protocol matched the result from the FTF motor skill domain in 80% of the 
patients with ONH. To our knowledge, there are no validated neurological protocols for 
visually impaired children. 
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3.5 NEURORADIOLOGICAL RE-EVALUATION 
In study III, neuroradiological imaging was reviewed by a neuroradiologist blinded to the 
patient’s clinical characteristics and the previous interpretation. Using a specific protocol, 
attention was especially directed towards the optic nerves, optic chiasm, bulbus oculi, 
adenohypophysis, neurohypophysis, pituitary infundibulum, hypothalamus, septum 
pellucidum, and corpus callosum, but other abnormalities were also sought after (e.g. 
schizencephaly, holoprosencephaly, hydrocephaly, cortical abnormalities including 
hippocampal malformations, white matter abnormalities, and PVL. The neurohypophysis was 
considered abnormal if the neurohypophysis bright spot was ectopic, or absent in 
combination with a pathological pituitary infundibulum. The neuroradiological findings were 
analysed in relation to laterality of ONH, neurological impairments, and PHD. 
Neuroradiological imaging was available for review in 51 cases (45 MRI and 6 computed 
tomography (CT) scans), whereas six patients had not undergone neuroimaging. MRI is 
superior to CT when examining the pituitary gland, and some other studies have simply 
excluded CT scans when evaluating brain malformations.81, 82 In contrast, we chose to include 
CT scans when they were assessable for the particular abnormality we were examining. 
Thereby, we could identify one patient with a large brain malformation including corpus 
callosum hypoplasia, schizencephaly, encephalocele, and hydrocephalus, and another patient 
with a hypoplastic adenohypophysis, and a third patient with corpus callosum agenesis and 
absent septum pellucidum. Nevertheless, the neuroimaging we reviewed was of different 
quality, especially with regard to the pituitary gland. The oldest CT scan was from 1994 and 
the oldest MRI from 1996. However, 88% of the reviewed neuroimaging was from the 2000s. 
3.6 HORMONAL ASSESSMENT 
In study III, the patients who had accepted clinical assessments were offered blood sampling 
for screening for hypopituitarism. Blood sampling was made for fasting morning glucose, 
cortisol, insulin-like growth factor-1 (IGF-1), insulin-like growth factor-binding protein 3 
(IGFBP-3), free T4, TSH, gonadotropins (LH, FSH), testosterone, estradiol, sodium, and 
prolactin. Medical records were reviewed for earlier diagnoses of endocrinopathies, hormonal 
treatment, and pathological growth curves.  
Absence of GHD was defined as normal height in relation to midparental target height 
(height SDS > -1.5 SD below target height), height SDS > -2.5 SD regardless of target 
height,120 and IGF-1 SDS > -2 SD 
(https://www.endocrinesciences.com/services/tools/calculator-igf1). Patients with a height 
SDS ≥ 0 SD and IGF-1 SDS > - 2SD were considered to have no GHD even if target height 
was missing. Patients with suspected GHD underwent provocative testing or recurrent blood 
sampling for spontaneous growth hormone (GH) secretion profile during 12-24 hours. Cut-
off for GH provocative testing was a peak GH level < 7µg/L, defining GHD. Patients treated 
with GH were secured to have a positive treatment response (delta-height SDS of at least 
+0.5 SDS over the first year) to verify the diagnoses of GHD. 
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ACTH deficiency was suspected in patients with low morning cortisol (< 100 nmol/L) and 
confirmed by a pathological stimulation test or repeated subnormal levels of cortisol. Central 
hypothyroidism was diagnosed if the free T4 level was below the reference range while TSH 
was in the lower reference range. Diabetes insipidus was suspected in cases of polydipsia, 
polyuria, or hypernatremia and was diagnosed with the water deprivation test or in infants, a 
positive response to desmopressin. Precocious puberty was defined in girls as Tanner pubertal 
stage B2 prior to the age of eight and in boys, a testis size of at least 4 ml prior to the age of 
nine. Gonadotropin deficiency was defined as no breast development by age 13 in females or 
testis size below 4 ml by age 14 in males. 
A paediatric endocrinologist assessed the patient’s pituitary function based on previous 
clinical evaluation, laboratory test results, and growth parameters. Subsequently, the 
prevalence of hormonal dysfunction was calculated for unilateral and bilateral ONH. PHDs 
were then analysed in relation to structural pituitary abnormalities on neuroradiological 
imaging, as well as to neonatal hypoglycemia (< 2.6 mmol/L) and treatment-demanding 
neonatal jaundice. 
Hormonal assessments are often difficult to evaluate and different criteria for diagnoses of 
PHD is probably one reason for the shifting prevalence of PHD in previous studies. We have 
taken into account the growth of the child in our assessment of GHD, and hormonal 
replacement therapy alone was not sufficient to confirm a PHD diagnosis. As a consequence, 
all patients classified as having GHD had a significant GH treatment response. Current 
guidelines for GH provocative testing stress that the threshold that distinguish normal from 
partial GHD (peak GH level 5-10 µg/L) responsive to treatment is not established, and that 
the diagnosis of GHD should not rely only on GH provocative testing.121 Our approach 
complies with these guidelines. 
The population-based cross-sectional cohort is the greatest strength of this study, but also the 
careful re-evaluation of each patient and strict inclusion criteria for diagnoses of PHD. Study 
limitations are that not all the patients participated in the blood sampling and a few patients 
were not sufficiently investigated for PHD, so they were excluded from some analyses.  
3.7 GENETIC ANALYSIS 
Genomic DNA derived from whole blood from 29 patients with ONH was collected 
according to standard protocols for genetic analyses in study IV. 
3.7.1 Array comparative genomic hybridization (array-CGH) 
A high-density custom-designed array-CGH was created using Agilents online web tool for 
array design, eArray. The used design was Agilent 2x400K HD-CGH microarray, consisting 
of approximately 400 000 oligonucleotide probes. Design and laboratory protocol for the 
array have been published previously.122 Detection limits for duplications were set to 0.3 and 
for deletions 0.6. All aberrations called by Cytosure Interpret Software were manually 
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inspected and classified according to the American College of Medical Genetics 
guidelines.123 
This custom-designed array-CGH reveals gene dose alterations and is able to detect both 
large copy number variants (CNVs) and small intragenic variants in 2000 target genes. 
3.7.2 Candidate gene panel 
A panel of 42 candidate genes previously associated with ONH, optic nerve aplasia, optic 
atrophy, or foveal hypoplasia was compiled by literature review in OMIM, PubMed, and the 
Developmental Brain Disorders Database. The panel included transcription factor genes (e.g. 
HESX1, SOX2, SOX3, SOX5, OTX2, PAX6, NR2F1, VAX1, ATOH7), tubulin genes, genes 
involved in chromatin remodeling, RNA splicing, or glycosylation, and other developmental 
genes (e.g. OPA1, CASK, COL4A1, COL4A2). The detailed candidate gene list, including 
references, is presented in paper IV, supplementary Table S1. 
The reason to include genes involved in optic nerve aplasia, optic atrophy, and foveal 
hypoplasia was that these disorders are closely related to ONH and may occur in the same 
individual. Thus, the disorders may have the same genetic aetiology. The chosen candidate 
genes have been associated with the above mentioned disorders in humans or in animal 
models. The candidate gene list has continuously been updated during the course of the study. 
3.7.3 Whole genome sequencing and variant validation 
Whole genome sequencing (WGS) was performed on 2.2 µg genomic DNA at National 
Genomics Infrastructure (NGI) Stockholm using the Illumina XTen platform. The samples 
were prepped using a paired end PCR-free library, resulting in an average read depth of 30X 
and a mean insert size of 350 base pairs. Sequencing data was processed using the NGI-piper 
pipeline (https://github.com/johandahlberg/piper). Structural variants were analysed using the 
FindSV pipeline (https://github.com/J35P312/FindSV), combining CNVnator124 and 
TIDDIT.125 Variant calling was performed using Bcftools126 and freebayes,127 the resulting 
vcf files were merged using GATK combine variants and annotated using VEP.128 Further, 
single nucleotide variants (SNVs) and indels (insertions or deletions of nucleotides) in the 42 
candidate genes were filtered with a maximum frequency of 0.01 in several normal variant 
databases including ExAC,129 the 1000 Genomes Project (1000G),130 and the Swedish 
population frequency database (SweFreq).131  
The variants were scored using SIFT (Sorting Intolerant From Tolerant)132 and PolyPhen,133 
the two most commonly used prediction tools for interpretation of genomic variation. Both 
algorithms predict whether a SNV has an effect on protein structure based on sequence 
conservation and the physical properties of amino acids. The PolyPhen score ranges from 0.0 
(tolerated) to 1.0 (deleterious), while SIFT score ranges the opposite, from 0.0 (deleterious) to 
1.0 (tolerated). The two models were interpreted together, and deleterious predictions set to 
moderate or high were kept. Finally, the variants were manually filtered based on their 
quality through inspection using IGV134 and previous literature. The remaining candidate 
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variants were confirmed with Sanger sequencing and parental samples were analysed to 
determine the mode of inheritance. 
To obtain a manageable number of variants we chose to filter the WGS data using an in silico 
panel of 42 candidate genes. Since the current knowledge of genetic causes of ONH is 
limited, the candidate gene list was far from complete. However, an advantage with WGS is 
that it enables analysis of additional candidate genes as they are discovered. For example, 
when we identified several candidate variants in COL4A1 we added the gene encoding 
collagen type IV alpha 2 chain (COL4A2), which forms a complex with COL4A1. 
Subsequently, we discovered three additional candidate variants in COL4A2. 
3.8 STATISTICAL METHODS 
The statistical methods used in this thesis are described in detail in the respective paper. In all 
the papers, a p-value < 0.05 was considered statistically significant. Statistical analyses were 
performed using STATXACT 4 (CYTEL Software Corporation, Cambridge, MA, USA) and 
STATISTICA 10.0 (StatSoft Inc, OK, USA) in paper I and STATISTICA 13 (StatSoft Inc, 
OK, USA) in paper II-IV. 
Independent samples t-test was used to compare continuous variables and when the 
assumptions underlying the t-test were not met, the Mann-Whitney U test and Kruskal-Wallis 
ANOVA by ranks were used instead. Analyses with chi-square test or Fisher’s exact test was 
performed to investigate differences in proportions of categorical variables. One-way 
ANOVA was used to investigate group differences between the mean index scores in paper 
II. In multivariable analyses, logistic regression was used to investigate categorical outcome 
in study III. In paper I, curvilinear regression was performed to measure the association 
between disc size parameters from the two methods.  
3.9 ETHICAL CONSIDERATIONS 
Ethical approval from the regional ethics committee in Stockholm was received for study I 
before commencing the first study. This approval was later supplemented for study II-IV 
before performance of these studies. Written informed consent for participation and 
publication of the results was obtained from the parents and from adolescents older than 15 
years of age. All studies were performed according to the Declaration of Helsinki. 
 
 
 
 
 
 
 
 
 
 
 28 
 
4 RESULTS 
4.1 PREVALENCE OF ONH 
In study I, we identified 76 patients with ONH who were below 18 years of age and living in 
the county of Stockholm in December 2009. The corresponding population at the time was 
438 897 individuals (Statistics Sweden) and the prevalence of ONH was thus determined to 
be 17.3/100 000. Of the 66 patients in the clinical study, 30 patients had unilateral ONH and 
36 had bilateral ONH. Accordingly, 45% had unilateral ONH. The same result was 
demonstrated in the clinical assessment of 53 patients (24 unilateral ONH (45%) and 29 
bilateral ONH (55%)). This is a high proportion of unilateral ONH, which contributed to the 
high prevalence of ONH and offers a good opportunity to investigate comorbidities in the 
unilateral group. 
There were 18% (12/65) who were blind, and 28% (18/65) of the patients had a BCVA < 0.3, 
and all of them had bilateral ONH (Table 1). In contrast, all patients with unilateral ONH had 
a binocular BCVA ≥ 0.3 and thereby mild or no visual impairment. 
 
Table 1. Best-corrected visual acuity (BCVA) in 65* patients with bilateral or unilateral optic nerve 
hypoplasia (ONH) 
 
 Bilateral ONH 
Total number of patients = 36 
BCVA binocular 
Unilateral ONH 
Total number of patients = 29* 
BCVA in the eye with ONH 
Amaurosis – < 0.05 12/36 13/29 
0.05 – < 0.1 1/36 3/29 
0.1 – < 0.3 
≥ 0.3 
5/36 
18/36 
8/29 
5/29 
*Information missing in one patient. Corrected and modified from paper I. 
 
 
4.2 PREVALENCE OF NEURODEVELOPMENTAL DISORDERS 
In study II, we examined the prevalence of neurodevelopmental disorders, with the focus on 
intellectual disability and ASD. Other conditions included in neurodevelopmental disorders 
are ADHD, specific learning disorders (dyslexia, dysgraphia, and dyscalculia), and 
communication disorders. 
Analysis of 40 FTF questionnaires (22 cases of bilateral and 18 cases of unilateral ONH) 
revealed more developmental problems in the bilateral group (median score 3.0 vs 0.5, p< 
0.05) in study I. To further investigate the prevalence of intellectual disability and ASD in 
patients with ONH, we collected 30 previously performed neuropsychological investigations 
and tested additional 15 children with the WISC-IV,109 and one adolescent with Wechsler 
Adult Intelligence Scale, Fourth edition110 in study II. Of the 16 patients tested in the study, 
15 had a normal intelligence, and one patient had a mild intellectual disability. In total, 
composite scores from the Wechsler Scales were available for analysis in 34 patients (16 
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ASD had mean FSIQ score 95.4 vs 94.0 in patients without ASD, p= 0.89). In addition, five 
patients (3 unilateral and two bilateral ONH) had a diagnosis of ADHD, and four of them 
also had an ASD. 
Intellectual disability was associated with severe visual impairment (BCVA 0.05 - < 0.1) and 
blindness. On the other hand, all patients with a BCVA < 0.1 had bilateral ONH, and within 
the bilateral group, there was no significant difference between the proportion of intellectual 
disability in patients with BCVA < 0.1 or ≥ 0.1, respectively. This suggests that visual 
impairment, in itself, did not increase the risk of intellectual disability. In addition, ASD did 
not correlate to BCVA (BCVA < 0.1 vs ≥ 0.1, p= 1.0). 
Table 2. Characteristics of the patients with ONH. Summary from paper II and III. 
Variables Total  Unilateral ONH Bilateral ONH P value* 
Laterality 65 30/65 (46) 35/65 (54)  
Sex  
    Female 
    Male 
 
33/65 (51) 
32/65 (49) 
 
13/30 (43) 
17/30 (57) 
 
20/35 (57) 
15/35 (43) 
0.32 
Agea, median (range), y 16.1 (8.1-27.5) 15.1 (9.9-25.5) 17.5 (8.1-27.5) 0.11 
Gestational ageb,  
median (range), w 
39 (24-43) 39 (24-43) 40 (27-43) 0.09 
Intellectual disability 20/55 (36) 2/23 (9) 18/32 (56) < 0.001* 
Autism spectrum disorder 7/42 (17) 2/21 (10) 5/21 (24) 0.41 
Neurological impairment 
     Gross motor dysfunction 
     Fine motor dysfunctionc 
24/51 (47) 
22/51 (43) 
15/50 (30) 
4/24 (17) 
4/24 (17) 
1/24 (4) 
20/27 (74) 
18/27 (67) 
14/26 (54) 
< 0.001* 
< 0.001* 
< 0.001* 
Cerebral palsy 6/65 (9) 1/30 (3) 5/35 (14) 0.21 
Epilepsy 9/65 (14) 1/30 (3) 8/35 (23) 0.03* 
Hypopituitarism 
     Any PHDd 
     Growth hormone deficiency 
     ACTH deficiency 
     Central hypothyroidism 
     Diabetes insipidus 
     Precocious puberty 
     Gonadotropin deficiency 
     Multiple PHD 
     Hyperprolactinemia 
 
13/45 (29) 
11/52 (21) 
8/49 (16) 
7/57 (12) 
5/63 (8) 
1/41 (2) 
1/31 (3) 
9/48 (19) 
4/32 (13) 
 
4/19 (21) 
3/22 (14) 
2/21 (10) 
1/25 (4) 
1/28 (4) 
1/15 (7) 
1/12 (8) 
2/21 (10) 
0/13 (0) 
 
9/26 (35) 
8/30 (27) 
6/28 (21) 
6/32 (19) 
4/35 (11) 
0/26 (0) 
0/19 (0) 
7/27 (26) 
4/19 (21) 
 
0.51 
0.32 
0.44 
0.12 
0.37 
0.37 
0.39 
0.26 
0.13 
Neuroradiological findings 
     Pituitary abnormalities 
     Absent septum pellucidum 
     Corpus callosum agenesis 
     White matter substance losse     
     Hippocampal  malformations 
27/51 (53) 
12/44 (27) 
9/51 (18) 
3/50 (6) 
13/46 (28) 
10/49 (20) 
7/22 (32) 
4/18 (22) 
4/22 (18) 
1/22 (5) 
3/18 (17) 
1/22 (5) 
20/29 (69) 
8/26 (31) 
5/29 (17) 
2/28 (7) 
10/28 (36) 
9/27 (33) 
0.01* 
0.73 
1.0 
1.0 
0.20 
0.02* 
Data are n/N (%), if not otherwise specified. The total number of patients varies depending on complete 
assessments, available laboratory tests, and assessable neuroradiological imaging. 
*P value < 0.05 was considered statistically significant. 
a Age at the analysis of the results in January 2018. b Gestational age, known in 62 patients, 29 unilateral and 
33 bilateral ONH. c Fine motor function could not be tested in a patient with bilateral ONH and intellectual 
disability. d Any pituitary hormone deficiency (PHD) disregarding unknown pubertal disturbances.e White 
matter substance loss including periventricular leukomalacia. 
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4.3 PREVALENCE OF NEUROLOGICAL DYSFUNCTION 
4.3.1 Motor impairments 
Neurological assessment was conducted in 51 patients (27 bilateral and 24 unilateral ONH), 
with a median age of 10.1 years (range 2.1-19.4 years). In study III, motor impairments were 
identified in 47% (24/51) of the patients. In bilateral ONH, 67% (18/27) had impairments in 
gross motor function and 54% (14/26) in fine motor function. In contrast, among patients 
with unilateral ONH 17% (4/24) had impairments in gross motor function and 4% (1/24) in 
fine motor function. Both impairments in gross motor function and fine motor function were 
significantly more prevalent in bilateral ONH (p< 0.001) (Table 2). Furthermore, motor 
impairments were correlated to intellectual disability (p< 0.001) and visual acuity measured 
by logMAR or BCVA < 0.05 (p= 0.01 and p= 0.001, respectively). Consequently, patients 
with a more pronounced visual impairment had a higher risk of motor impairment.  
In the neurological assessment, it was noted that 33% of the patients (older than four years of 
age) were left-handed, but left-handedness was not associated with bilateral ONH, gross or 
fine motor function impairment, intellectual disability, or ASD. Therefore, left-handedness 
does not seem to have a prognostic value. 
More noteworthy, 9% (6/65) of the cohort had a diagnosis of cerebral palsy, without 
association with laterality of ONH, but all of them had brain abnormalities (Table 2). In 
addition, one patient had a hereditary spastic paraparesis and three patients with bilateral 
ONH had severe neurological impairments not classified as cerebral palsy, but were 
dependent on physical assistance and wheelchair. 
4.3.2 Epilepsy 
The prevalence of epilepsy was 14% (9/65) and there was a higher risk in bilateral ONH than 
unilateral ONH (23% vs 3%, p= 0.03) (Table 2). Three patients with bilateral ONH had 
infantile spasms. 
4.4 NEURORADIOLOGICAL FINDINGS 
In study III, pathological neuroradiological findings (brain malformations and white matter 
substance loss) were detected in 53% (27/51) (Table 2). Bilateral ONH was associated with a 
higher risk of brain abnormalities than unilateral ONH (69% vs 32%, p= 0.01). Absent 
septum pellucidum was found in 18%, but did not correlate to laterality, PHD, structural 
abnormalities, blindness, intellectual disability, ASD, or motor impairments. In contrast, 
absent septum pellucidum was associated with corpus callosum agenesis (p= 0.004). Three 
patients had corpus callosum agenesis and two patients had corpus callosum hypoplasia. 
Together these conditions constitute corpus callosum dysgenesis, which was associated with 
intellectual disability, motor impairment, and epilepsy (p< 0.05). 
Structural pituitary abnormalities were identified in 27% (12/44) and did not correlate to 
laterality. All nine patients with PHD and assessable pituitary gland had an abnormal 
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pituitary, and no patient with a normal pituitary had evidence of any PHD (Table 3). 
Consequently, an abnormal pituitary had a very strong correlation to PHD, both single and 
multiple PHD (p< 0.001). In addition, the five patients with diabetes insipidus had an 
abnormal neurohypophysis (three were absent and two were ectopic). 
 
Table 3. Hypopituitarism associated with structural pituitary abnormality, paper III 
 Hypopituitarism Normal 
endocrinological 
evaluation 
Total 
Pituitary abnormality 9 3 12 
Normal pituitary 0 22 22 
Total 9 25 34 
 Sensitivity, 100% Specificity, 88% p< 0.001 
 
Furthermore, we found hippocampal malformations in 20% (10/49) of the patients and it was 
more common in bilateral ONH (33% vs 5%, p= 0.02). Hippocampal malformations 
increased the risk of epilepsy (p= 0.03, adjusted for bilateral ONH). Finally, there was a high 
prevalence of white matter substance loss (28%, 13/46), including six patients with PVL. The 
white matter substance loss was most often located occipitally, dorso-lateral to posterior parts 
of the lateral ventricles. 
4.5 PREVALENCE OF PITUITARY HORMONE DEFICIENCY 
The prevalence of PHD in study III was 29% (13/45) and did not differ significantly between 
unilateral and bilateral ONH (21% vs 35%, p= 0.51) (Table 2). GHD was the most common 
PHD (21%), followed by ACTH deficiency (16%), central hypothyroidism (12%), diabetes 
insipidus (8%), gonadotropin deficiency (3%), and precocious puberty (2%). Multiple PHD 
(more than one PHD) was identified in 19% (9/48) of the patients with ONH. Of note, only 
31 patients had passed the upper limit for a normal start of puberty and were clinically 
assessed for puberty. 
The median age at diagnosis of the first PHD was 0.8 year (range 0-8.7 years), and 85% of 
the patients with hypopituitarism had developed their first PHD by the age of five (Figure 
10). Four patients were first diagnosed with ACTH deficiency, and all eight patients with 
ACTH deficiency were diagnosed before five year of age (Table 4 and Figure 11).  
Altogether, 33 PHD diagnoses were identified in 13 patients, and 79% of the PHDs were 
diagnosed before five years of age (Table 4 and Figure 11). However, the oldest patient 
diagnosed with a PHD was a 16-year-old boy with previous multiple PHD, who also 
developed central hypothyroidism. Late-onset central hypothyroidism was the most common 
PHD diagnosed in school age (Figure 11). Central hypothyroidism was not associated with 
intellectual disability (p= 1.0). 
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Table 4. Pattern of pituitary hormone deficiency (PHD) in 13 patients. The PHDs are numbered in order of 
diagnosis. 
Patient GH ACTH TSH ADH FSH/LH Number of PHD 
for each patient 
Patient 1 3 1 4 2  4 
Patient 2 1     1 
Patient 3 2 1 3   3 
Patient 4 1     1 
Patient 5 1  2   2 
Patient 6 3 1 2   3 
Patient 7 1 2 4  3 4 
Patient 8 1 2 3* 4  4 
Patient 9 3 1  2  3 
Patient 10  2  1  2 
Patient 11     1 1 
Patient 12 2 3 4 1  4 
Patient 13 1     1 
Total number of 
each PHD 
11 8 7 5 2  
*Central hypothyroidism was diagnosed at the same age as ACTH deficiency. GH, growth hormone; ACTH, 
adrenocorticotropic hormone; TSH, thyroid-stimulating hormone; ADH, antidiuretic hormone; FSH, follicle-
stimulating hormone; LH, luteinizing hormone. 
 
Potential neonatal indicators of hormonal dysfunction, such as hypoglycemia and treatment-
demanding jaundice were found in 16% (10/62) and 23% (14/61), respectively. Neonatal 
hypoglycemia was more common in the bilateral group (28% vs 3%, p= 0.01), and in patients 
with central hypothyroidism, ACTH deficiency, GHD, and multiple PHD (p< 0.009, adjusted 
for bilateral ONH). Similarly, patients who had been treated for neonatal jaundice more often 
had ACTH deficiency or multiple PHD (p= 0.006 and p=0.01, respectively, adjusted for 
gestational age), but jaundice did not correlate to laterality. 
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4.6 GENETIC CANDIDATE VARIANTS 
In study IV, we performed a systematic screening for rare genomic variants in 29 patients 
with ONH and identified 13 rare SNVs in 12 patients and one rare CNV in one patient (Table 
5).  
Table 5. Clinical phenotypes and identified candidate genes in 13 patients with ONH. Summary from paper IV. 
Case Sex Gene Candidate 
variant 
Inheritance ONH Neuro PHD Other    
malformations 
2 M SPG7 p.(Ala510Val) Maternal Bilat 
Blind 
ID,CP,EP - Microcephaly, 
WMA, 
facial 
asymmetry 
4 M COL4A2 p.(Pro650Ser) Paternal Bilat Autistic 
traits 
- - 
5 M CYP26A1 p.(Ile395Thr) Maternal Bilat - MPHD Pituitary 
abnormality 
9 F PAX6 p.(Ter423Lys) Ni Unilat - - - 
11 M COL4A1 p.(Gly948Ser) De novo Bilat 
Blind 
ID,CP,EP - CD, 
calcification, 
WMA, thin CC, 
microcephaly 
14 M UBE3B p.(Ala988Thr) Maternal Bilat -  - Unilat 
syndactyly toes  
17 M COL4A2 p.(Gly1663Ser) Maternal,  
paternal  
Bilat ASD, 
hyposmia 
MPHD Pituitary and 
jaw 
abnormalities 
18 F SOX5 
 
Heterozygous 
deletion  
exon 7-18 
Not paternal Bilat ID, autistic 
traits 
- VSD 
19 M CYP26C1 p.(Gln284fs) Ni Unilat - - - 
20 M CYP26C1 p.(Gln119Pro) Paternal Unilat - - - 
21 F COL4A1 
OPA1 
p.(Pro54Leu) 
p.(Ile382Met) 
Paternal, 
Paternal 
Unilat - - - 
27 F COL4A2 p.(Gly729Arg) Maternal Unilat ID - Hypertelorism 
29 F COL4A1 p.(Pro484Thr) Maternal Bilat ID - Colpocephaly,  
CC agenesis, 
SP agenesis, 
MTS, 
arachnoid cyst, 
hypertelorism, 
ovarian cysts, 
liver and uterus 
abnormalities, 
bowel 
malrotation 
ONH, optic nerve hypoplasia; Neuro, neurological dysfunction; PHD, pituitary hormone deficiency; Bilat, 
bilateral; ID, intellectual disability; CP, cerebral palsy; EP, epilepsy; WMA, white matter abnormalities; 
MPHD, multiple pituitary hormone deficiency; Ni, no information; Unilat, unilateral; CD, cortical 
destruction; CC, corpus callosum; ASD, autism spectrum disorder; VSD, ventricular septal defect; SP, septum 
pellucidum; MTS, molar tooth sign. 
 
4.6.1 Single nucleotide variants (SNVs) 
We identified rare heterozygous variants in COL4A1 in three patients and variants in 
COL4A2 in additional three patients. Consequently, 21% (6/29) of the patients with ONH 
carried a rare missense variant in either of these two genes. Three of the variants were 
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especially interesting. The first was the rare variant COL4A1 p.(Gly948Ser) confirmed to be 
de novo by segregation studies. The same variant has previously been described as 
pathogenic in an individual with porencephaly, calcification, cerebral palsy, epilepsy, and 
intellectual disability.43 Our patient had similar symptoms, which strengthens the 
pathogenicity of COL4A1 p.(Gly948Ser). The second variant of interest was a homozygous 
mutation in COL4A2 p.(Gly1663Ser), with each allele inherited from two unrelated parents. 
Interestingly, there are no homozygous individuals with this variant reported in the ExAC 
database.129  
The third patient had two rare variants, a heterozygous missense variant in COL4A1 
p.(Pro54Leu) and a heterozygous missense variant in OPA1 p.(Ile382Met). Mutations in 
OPA1 are associated with optic atrophy 1, but it has previously been suggested that OPA1 
may also be involved in ONH.45 This OPA1 variant is enriched in individuals with autosomal 
dominant optic atrophy, but is also present in both the dbSNP and ExAC databases 
(rs143319805).135 The rare variants in OPA1 and COL4A1 were inherited from the father 
who had strabismus as a child, suffered from a traumatic macular haemorrhage in the left eye 
as an adolescent and went through cataract surgery in adulthood. He was never diagnosed 
with ONH, but suspected to have a traumatic optic atrophy in his left eye. 
Another interesting finding was a PAX6 variant p.(Ter423Lys) which causes a lost stop 
codon, similar to the variant p.(Ter423Leu) that has previously been described in aniridia.136 
Although parental DNA was unavailable for analysis, this variant is a likely candidate since 
other variants in PAX6 have been described in patients with ONH.136, 137 
In summary, three of the SNVs (COL4A1 p.(Gly948Ser), COL4A2 p.(Gly1663Ser), and 
PAX6 p.(Ter423Lys)) were assessed as likely pathogenic, and the remaining 10 were 
heterozygous variants of unknown clinical significance. 
4.6.2 Copy number variants (CNVs) 
Array-CGH revealed one rare CNV, which was a heterozygous deletion of 341 kb at 12p12.1 
involving exons 7-18 of SOX5. SOX5 has previously been described in Lamb-Schaffer 
syndrome, an autosomal dominant syndrome with varying phenotype including ONH, optic 
atrophy, developmental delay, behavioural problems, poor expressive speech, mild 
dysmorphic features, and skeletal abnormalities.138, 139 The affected patient had bilateral 
ONH, intellectual disability, autistic traits, and a small ventricular septal defect. DNA was 
only available from the father and he did not carry the deletion. Subsequently, the SOX5 
deletion was assessed as likely pathogenic. 
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5 DISCUSSION 
The prevalence of ONH was determined to be 17.3/100 000 in patients below 18 years of age 
in Stockholm. This is the highest prevalence of ONH that has been reported, and 45% of the 
patients had unilateral ONH. Consequently, this is a unique population-based cohort and a 
good foundation for further prevalence studies of associated disorders. Children with ONH 
had a high risk of neurodevelopmental disorders and the prevalence of intellectual disability 
was as high as 56% in patients with bilateral ONH and 9% in unilateral ONH. ASDs were 
diagnosed in 17% of the cohort and 29% had hypopituitarism. 
The high prevalence of comorbidities underlines that ONH is a serious condition with a high 
risk of neurological and hormonal dysfunctions. Our studies clearly show that bilateral ONH 
is associated with a higher risk of neurodevelopmental disorders and motor impairment 
compared to unilateral ONH and is very likely caused by a more severe adverse impact on the 
developing brain. In contrast, prevalence of hormonal dysfunction and structural pituitary 
abnormalities did not differ between unilateral and bilateral ONH. 
5.1 HIGHER PREVALENCE OF ONH 
The prevalence of ONH in study I (17.3/100 000 children) was higher than the previously 
reported prevalence from Northwest England, which was estimated to be 10.9/100 000 in 
children younger than 16 years of age in 2006.15 This may be due to a difference over time 
with an increasing prevalence of ONH as has previously been suggested.13 However, the 
higher prevalence in our study is more likely due to the high proportion of unilateral ONH 
(45%), which in turn probably is a result of increased awareness of ONH and the population-
based design of our study. In contrast to the study of Patel et al, the present cohort also 
included a high proportion of patients with bilateral ONH and mild or no visual impairment 
(50%).15 On the other hand, we found that approximately 4/100 000 children had a BCVA < 
0.3 (i.e. at least moderate visual impairment), which is actually lower than the previous 
Swedish report of 7/100 000 births.14  
In early studies, the proportion of unilateral ONH was similar to bilateral ONH,140, 141 but 
these studies were small and not population-based. Later reports have suggested that bilateral 
ONH is more common than unilateral ONH,31, 74 and in a large prospective study, 82% of the 
patients had bilateral ONH.16 However, depending on the study design cohorts are more or 
less selective, and there is a lack of population-based studies. Unfortunately, the prevalence 
study of Patel et al did not present the proportion of unilateral and bilateral ONH.15 
Therefore, it is very interesting that we found that unilateral ONH was almost as common as 
bilateral ONH. Study I supports our hypothesis that unilateral ONH as well as bilateral ONH 
with mild visual impairment are underrepresented in many studies. We believe that the high 
prevalence of ONH, the inclusion of 45% with unilateral ONH and approximately 70% with 
mild visual impairment are indicative of a less selected cohort. 
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5.2 HIGH RISK OF NEURODEVELOPMENTAL DISORDERS 
We showed that children with bilateral ONH have a higher risk of intellectual disability than 
those with unilateral ONH (56% vs 9%). In addition, patients with bilateral disease had 
significantly lower mean FSIQ scores. This is consistent with the publication of Skarf et al, 
which described normal development in children with unilateral ONH (12% of the cohort), 
but in the bilateral group with poor vision, 46% had a development delay.74 Garcia-Filion et 
al reported a higher prevalence of developmental delay, 78% in bilateral and 39% in 
unilateral ONH, using the Battelle Developmental Inventory in a prospective study from a 
referral center in the USA.16 These two studies focused on the wider concept of 
developmental delay, while we chose to examine the prevalence of intellectual disability, as it 
has a larger impact on the child’s everyday life. There is no other population-based study that 
has examined the difference in prevalence of intellectual disability in children with unilateral 
and bilateral ONH. 
The prevalence of ASD was 24% in the bilateral group and 10% in the unilateral group. 
Although the difference was not statistically significant, study II was the first study to present 
ASD prevalence in unilateral ONH. We described a lower prevalence of ASD (17%) than 
previously reported, but the prevalence of ASD in the bilateral group (24%) was similar to 
the results of 29-33% from other studies.88, 90, 142 We believe this discrepancy was due to the 
population-based design of our study.  
Furthermore, it is notable that the patients in our cohort received the ASD diagnoses late, at a 
median age of 10.3 years (range 5.8-15.6 years). This likely reflects the lack of knowledge 
about the high prevalence of ASD in children with ONH, failure to recognize autistic 
symptoms, confusion with blindism,143 but also a lack of validated testing instruments for 
visually impaired children. Our findings show that children with unilateral ONH also have a 
high risk of neurodevelopmental disorders compared to the general population, where the 
prevalence of intellectual disability is 1-2% in Sweden,144 and the prevalence of ASD is 1% 
in Stockholm.145 It therefore highlights the need of screening for neurodevelopmental 
disorders in all children with ONH before starting school. 
Early neurodevelopmental diagnoses are important for the child’s development and for the 
choice of an optimal school setting, and especially the dual disability of blindness and ASD is 
challenging.146 In these cases, specific pedagogical support and evidence-based practices for 
ASD is needed and has to be adapted for the visual impairment.146 
In general, coexistence of neurodevelopmental disorders is very common and the symptoms 
overlap. Therefore, the term ESSENCE (Early Symptomatic Syndromes Eliciting 
Neurodevelopmental Clinical Examinations) has been coined to emphasize that children with 
neuropsychiatric symptoms need a multidisciplinary assessment.147 In our cohort, there were 
several individuals who had more than one neurodevelopmental disorder and in some 
patients, the diagnosis changed over time. The large amount of neuropsychiatric symptoms is 
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demonstrated by the fact that 46% of the patients with ONH had previously been tested 
neuropsychologically, once or several times.  
We found that blindness and severe visual impairment was associated with an increased risk 
of intellectual disability, but not with ASD. However, all the patients with a BCVA < 0.1 had 
bilateral ONH, and within the bilateral group we found no significant difference of the 
proportion of intellectual disability that correlated to BCVA. This suggests that it was not the 
visual impairment per se that increased the risk of intellectual disability, but rather that it was 
a symptom of a more severe bilateral ONH disease. Two other reports described higher 
frequencies of autistic symptoms in children with ONH/SOD and profound visual impairment 
compared to children with ONH/SOD and better vision, but neither did they find any 
significantly increased risk of the diagnose ASD correlating to visual acuity.90, 142 Our results 
indicate that the neurodevelopmental disorders seen in children with ONH are more likely to 
be a result of brain dysfunction rather than a consequence of visual impairment. 
5.3 NEUROLOGICAL DYSFUNCTION 
Similar to the prevalence of intellectual disability, we identified a higher risk of neurological 
impairments in patients with bilateral ONH in study III. In total, impairments in gross and/or 
fine motor function were significantly more common in bilateral ONH than unilateral ONH 
(74% vs 17%). There is no comparable study, but Fahnehjelm et al reported hypotonia, 
dyskinesia, or motor delay in 21% in a selected cohort with bilateral ONH and severe visual 
impairment,88 and Signorini et al described a high degree of motor clumsiness in a 
retrospective study.91  The majority of the motor impairments we detected, could be described 
as minor neurological dysfunction,119 but 9% of the patients had a diagnosis of cerebral palsy 
and additional four patients had so severe neurological impairments that they were dependent 
on assistance. Several other studies have reported a similar prevalence of cerebral palsy 
ranging from 9-13%.31, 92, 94 In consistence with Garcia et al, we found no statistically 
significant difference in the prevalence of cerebral palsy between unilateral and bilateral 
ONH.94 Moreover, we found that motor impairments were associated with intellectual 
disability and visual impairment, which is well known and reflects that delayed motor skills 
are often a part of global developmental delay and severe visual impairment inhibits the 
child’s ability to practice motor skills. 
Epilepsy was diagnosed in 14% of the cohort and it was significantly more common in the 
bilateral group (23% vs 3%). One of the few ONH studies that has reported on this, found 
epilepsy in 21% of the patients with bilateral ONH and severe visual impairment, which is 
comparable to our bilateral group.88 In the general population, the prevalence of epilepsy in 
Swedish children is much lower (0.9%).148 Furthermore, we found that hippocampal 
malformations increased the risk of epilepsy. 
5.4 HORMONAL DYSFUNCTION 
Hypopituitarism can be life threatening, both due to ACTH deficiency and subsequent 
hypoglycemia and profound hypotension, as well as to diabetes insipidus causing severe 
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volume depletion and electrolyte abnormalities resulting in circulatory shock, seizures, and 
coma.149 Garcia-Filion et al reported that 52% of the children with ONH and hypothyroidism 
were undiagnosed before enrollment in the study, and they reported that hypothyroidism was 
a risk factor for developmental delay.16  
Despite the high risk of complications in patients with undiagnosed and untreated hormone 
deficiency, some ophthalmologists do not refer children with ONH to an endocrinologist, 
especially in unilateral disease. On the other hand, sometimes endocrinologists choose not to 
further investigate or follow-up children with ONH. Therefore, it is very important to 
determine the prevalence of PHD in ONH and to investigate if there is a difference in the 
frequency of PHD between unilateral and bilateral ONH. 
We found a prevalence of PHD of 29%, which is in congruence with the cross-sectional study 
of Ramakrishnaiah et al (28%).80 It is however, lower than in many other studies,79, 81, 82 
which is likely due to the population-based design, with 46% unilateral ONH and patients 
with less severe visual impairment. In addition, we have been stricter in our inclusion criteria 
for GHD, which is the most common PHD. In contrast to Garcia-Fillion et al,16 we did not 
perform provocative testing in all the patients. We first evaluated growth curves and IGF-
1/IGFBP-3 and only patients with suspected GHD was investigated further.  
Several other researchers have used a cut-off level of a stimulated GH peak of 10 µg/L,79, 81, 
150 while we used the cut-off level of 7 µg/L which is more closely correlated to GHD.121 A 
higher cut-off level increases the risk of capturing individuals without GHD, especially if not 
considering the growth curve or response to GH treatment. Furthermore, we re-evaluated all 
the PHD diagnoses, and hormonal replacement therapy was not considered sufficient to 
confirm a diagnosis. Consequently, we excluded cases of primary hypothyroidism, nocturnal 
enuresis, and one patient on GH treatment. 
An important finding was that there was no statistically significant difference in the 
prevalence of PHD between unilateral and bilateral ONH. This is consistent with the studies 
of Ahmad and Alyahyawi and coworkers.66, 82 Therefore, children with unilateral ONH 
should be followed-up endocrinologically as closely as in bilateral ONH. Our results further 
showed that 85% of the patients with PHD had their first PHD diagnosis before five years of 
age, similar to Alyahyawi et al (82%).82 In addition, 79% of all the PHD diagnoses and 100% 
of the ACTH deficiencies were detected before the age of five. Ryabets-Lienhard et al 
recommended screening for hypopituitarism every fourth to sixth months in the first three 
years of life and then annually.151 In our cohort, only 57% of the PHD diagnoses were 
confirmed at three years of age, and our results suggest a more frequent endocrine follow-up 
during the first five years of age. Due to the risk of pubertal disturbances and later evolving 
PHD, especially central hypothyroidism, more sparsely hormonal assessments should 
continue at least until puberty is completed. 
Many patients in our cohort were not previously examined for PHD to a sufficient degree. In 
medical records, we saw examples of both good and bad endocrinological investigations, 
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examples of how hormonal results can be interpreted differently, and different opinions about 
treatment. Some parents have also chosen not to participate in screening of PHD in their 
children because they wanted them to stay small/short to facilitate the care of children with 
neurological dysfunction. In addition, we found a pattern of doctor’s delay at the neurological 
departments, where children with severe neurological disorders too often were not 
endocrinologically investigated despite growth failure and where the ONH diagnosis seemed 
to be forgotten. It is understandable that the neurological situation, often with epilepsy, gets 
more attention, but this stresses the importance that these children also need to be followed-
up at the endocrinological department. 
5.5 BRAIN ABNORMALITIES 
We detected structural pituitary abnormalities in 27% of the patients and in all of whom had 
PHD. Thus, the sensitivity was 100%. Ramakrishnaiah et al reported neurohypophyseal 
abnormalities in 33% of the cohort and described 96% sensitivity and 92% specificity for 
PHD,80 while Garcia-Filion et al reported that only 9% of the children with ONH had 
pituitary abnormalities, with 13% sensitivity and 100% specificity for PHD.81 In summary, 
there is convincing evidence that pituitary abnormalities are highly predictive of PHD, but the 
sensitivity for PHD is unreliable. Study III is limited by not having assessable 
neuroradiological imaging on all the patients, and assessment of the pituitary was missing in 
four patients with PHD. Still, Garcia-Filion et al have reported enough patients with 
hypopituitarism and a normal structural pituitary on MRI to make it impossible to rule out 
PHD from a patient with a normal MRI.81 This is very important for the clinical evaluation. 
Less important or not important at all, is the presence of the septum pellucidum. Still, it is 
evident that the concept of SOD is very much in use both clinically and in research.152, 153 
However, our results provide further evidence for the lack of clinical significance of an 
absent septum pellucidum as we could not find any association with laterality, PHD, 
structural pituitary abnormality, motor impairment, intellectual disability, or ASD. 
Nonetheless, absent septum pellucidum was associated with corpus callosum agenesis, which 
is understandable as the septum normally is attached to the corpus callosum. Corpus callosum 
agenesis increased the risk of intellectual disability, cerebral palsy, and epilepsy, but not the 
risk of PHD. In our opinion, SOD is a misleading term that increases the risk of children with 
ONH and a complete septum pellucidum not being properly investigated for hypopituitarism. 
Septum pellucidum should not be used as a risk marker for PHD.  
Altogether, brain abnormalities were identified in 53% of the cohort, and bilateral ONH was 
associated with a higher risk than unilateral ONH. Due to our population-based design, our 
prevalence could be expected to be lower than previous reports of 60-74% with brain 
abnormalities.81, 94 The higher frequency of brain malformations in bilateral ONH supports 
the theory that bilateral ONH is a result of a more severe insult to the developing brain. In 
addition, we detected hippocampal malformations in 20% of the patients, significantly more 
common in the bilateral group. This malformation has previously been noted by Riedl et al in 
ONH patients.150 Finally, 28% of the patients had white matter substance loss, which could 
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be an indicator of a prenatal insult that may have affected the visual pathway and contributed 
to retrograde trans-synaptic degeneration. 
5.6 RARE VARIANTS IN COL4A1 AND COL4A2 
Two of the rare variants in COL4A1 and COL4A2 were especially interesting. They were the 
heterozygous de novo variant COL4A1 p.(Gly948Ser) previously described as pathogenic43 
and the homozygous variant COL4A2 p.(Gly1663Ser).  
COL4A1 and COL4A2 are located on opposite strands at 13q34 and have a common 
promotor. COL4A1 and COL4A2 respectively encode the alpha-1 and alpha-2 subunits of 
collagen type IV. Two alpha-1 chains and one alpha-2 chain form a heterotrimer.154 Collagen 
type IV is not only essential for basement membranes, but is also involved in developmental 
processes, such as cell adhesion, migration, proliferation, and differentiation.154 This makes 
the COL4A1 and COL4A2 genes very interesting from a developmental perspective. 
Col4a1+/Δex41 mutant mice have been reported to have changes in the retinal inner limiting 
membrane besides ONH, suggesting that abnormalities of the basement membranes may 
cause ONH.155 
Mutations in COL4A1 have primarily been associated with small-vessel brain disease (e.g. 
porencephaly, schizencephaly, and cerebrovascular disease), but ophthalmological disorders 
have also been described (e.g. retinal arterial tortuosity, congenital cataract, anterior segment 
dysgenesis, glaucoma, microphthalmia, anophthalmia, optic atrophy, and ONH).43, 44, 156 
Similarly, mutations in COL4A2 have been associated with intracerebral haemorrhages, 
porencephaly, optic atrophy, and ONH.44, 157-160 However, only a few patients with ONH and 
mutations in COL4A1 or COL4A2 have been reported in the literature.43, 157 
Regarding mutations in COL4A1 and COL4A2, there seems to be an autosomal dominant 
pattern of inheritance. Therefore, our homozygous variant in COL4A2 is of interest and 
further functional study is necessary to conclude whether it is pathogenic or not. Moreover, 
mutations in COL4A1 and COL4A2 show a broad phenotypic variation with reduced 
penetrance. For this reason, inherited rare variants could not be assessed as likely benign, and 
were assessed as variants of unknown clinical significance. It may be speculated if these 
variants could constitute a genetic vulnerability and cause ONH in combination with a second 
hit, genetic or environmental. Accordingly, the combination of rare variants in COL4A1 and 
OPA1 is interesting, and the affected patient will be further investigated with OCT. In 
general, functional studies would be helpful to determine the clinical significance of the 
inherited heterozygous variants. 
Furthermore, the location of the variants in COL4A1 and COL4A2 seems to be of major 
importance. We found three rare variants in COL4A1 and three rare variants in COL4A2, and 
two of the variants were located in the triple helix domain and resulted in the substitution of a 
glycine (Figure 12). The first was the heterozygous de novo variant COL4A1 p.(Gly948Ser), 
and the second was a heterozygous variant COL4A2 p.(Gly729Arg). The triple amino repeats, 
constituted by glycine in every third position in the triple helix domain are essential for the 
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Although we have reported the highest known prevalence of ONH, the total number of 
patients was only 76 who were below 18 years of age. In the research field of ONH, this is a 
rather large cohort, but not in general for prevalence studies. Study I was performed in the 
county of Stockholm, and the cohort is likely representative for Sweden and probably at least 
for Scandinavia. However, a multi-center study in Sweden would have increased the power 
of the study, but it is uncertain if we could have had the same coverage, resulting in a high 
prevalence of ONH. 
The prevalence of ASD and hypopituitarism did not differ significantly between unilateral 
and bilateral ONH, but it is possible that a larger cohort may have shown a difference in 
prevalence, and this should be studied further. 
In study II, it is a study limitation that patients were examined using different 
neuropsychological tests and no standardized autism assessment was conducted. It would 
have been preferable to use a model of modified ADOS,114 even though there is a lack of 
validated testing instruments for ASD in visually impaired children. However, it was not 
practically feasible at the time being, and we used the FTF to screen for ASD. Borderline 
cases may have been missed and might have affected the prevalence of ASD. 
The neurological assessment of motor impairments would have been improved by additional 
assessment by a physiotherapist and an occupational therapist. But, the neurological 
assessment was performed at the same visit as the ophthalmological assessment and 
additional investigations would have required more visits for the patients, which could have 
affected the participation rate. 
The lower prevalence of neurodevelopmental disorders, hypopituitarism and brain 
abnormalities in our cohort are likely a result of the population-based approach, but may also 
reflect that ONH is due to different aetiologies in different populations. 
The endocrinological assessment was limited by not having blood sampling for evaluation of 
all PHDs in every patient. Thirty-one patients participated in the study blood-sampling and 
another 29 patients had results from clinical endocrinological blood analyses, but five patients 
did not have any results. A prospective design would have been preferable, and may be 
possible in a future follow-up program. Assessment of puberty is of particular interest since 
pubertal disturbances are not well studied, but clinical assessment of pubertal stages was not 
included in study III. Hence, for the assessment of Tanner pubertal stages and testis size, we 
had to rely on other clinicians’ documentation in the medical records. In addition, 
neuroradiology was not performed in all patients, and especially assessable imaging of the 
pituitary was lacking in four patients with PHD. 
The last limitation to be mentioned is that we performed WGS, but filtered the data for the 
candidate genes. By analysing the whole genome, new candidate genes probably will be 
found. 
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5.8 ONH IN A DEVELOPMENTAL PERSPECTIVE 
ONH is a congenital malformation, and it is likely that monogenic, polygenic, and 
environmental factors, single or in combinations, can be causative. As previously described, 
genetic mutations and ethanol may affect the retinal progenitor cells at an early stage,23 but 
other studies have indicated that ONH is more likely a result of prenatal events affecting the 
optic nerve, optic tract, or the optic radiation, subsequently, leading to a retrograde 
degeneration.71, 162  
Furthermore, Lubinsky hypothesized that ONH/SOD were due to a vascular disruptive 
sequence and suggested involvement of the proximal trunk of the anterior cerebral artery.59 
Mutations in COL4A1 and COL4A2 may increase the risk of a vascular insult, and this could 
be an underlying mechanism. Both the patient with the de novo variant COL4A1 
p.(Gly948Ser) and the previously reported patient with the same variant had calcifications on 
MRI, which may indicate earlier bleeding. A vascular insult is an interesting hypothesis 
explaining why hypopituitarism so often occurs in patients with ONH.59 In addition, due to 
the strong connection between ONH and pituitary dysfunction, there are likely undiscovered 
common genetic aetiologies affecting the development of the optic nerve, the pituitary gland, 
and hypothalamus. 
Previous research suggests that the overall mutational burden matters.163 We speculate that 
the broad phenotype seen in patients with ONH may be explained by the disease gene and the 
overall mutational burden, modified by the regulatory landscape and environmental factors. 
This could also be seen as an overlapping spectrum between environmental factors and 
genetic abnormalities. This would explain the reduced penetrance reported in many of the 
candidate genes and why so few family members are affected. 
Neurodevelopmental disorders, motor impairments, and brain malformations were more 
common in bilateral ONH indicating that bilateral ONH is a more severe developmental 
disorder. Most likely, bilateral ONH is caused by an earlier event affecting more 
developmental processes. However, it should be emphasized that hypopituitarism was not 
associated with laterality and the results highlight the importance that all children with ONH 
should be followed-up endocrinologically. Isolated ONH, without any combination with 
neurodevelopmental disorder, other major congenital malformation, or hypopituitarism, was 
found in 26% (13/50) of the patients and did not differ significantly between unilateral and 
bilateral ONH (42% vs 16%, p= 0.054). This is because of the high prevalence of PHD in 
both groups. 
Even though ONH may be caused by genetic mutations and environmental factors such as 
ethanol, many cases are probably secondary to other brain malformations, intracerebral 
bleeding, and white matter substance loss. The long way of connections from the retina, 
through the optic nerve to the visual cortex makes the optic nerve vulnerable. Despite the 
different aetiologies, ONH is an indicator of a deviating event during development. 
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5.9 CLINICAL IMPLICATIONS 
The findings presented in this thesis, has several clinical implications. Firstly, it emphasizes 
the importance of a correct diagnosis in children with poor visual function or blindness. Not 
only is this important for the parents, but also since the diagnosis of ONH has a large impact 
on the need of further investigations. At the same time, diagnostics can be hard due to 
nystagmus, poor cooperation, and difficulties in getting fundus photographies to confirm the 
suspicion of ONH. This study suggests that the simple manual Zeki method is reliable and 
can be used in most patients, from a preschool age, to establish the diagnosis. 
Secondly, the ophthalmologist should refer all children with ONH (i.e. both unilateral and 
bilateral ONH) to an endocrinologist for assessment and follow-up. In addition, a referral 
should be sent to a neuropaediatrician for assessment of the development and neurological 
function. 
Thirdly, a MRI of the brain and the orbits is valuable to evaluate the optic nerves and detect 
other brain malformations. In particular, the assessment of the pituitary gland is important 
from a prognostic point of view. Therefore, it is essential to ask for pituitary abnormalities to 
ensure that adequate MRI protocols are used. An absent septum pellucidum, as the only 
finding, does not have any clinical impact. If anesthesia is necessary, ACTH deficiency must 
first be excluded. 
When there is a structural pituitary abnormality the risk of PHD is close to 100%. 
Nevertheless, a normal pituitary gland does not rule out PHD and all children with ONH 
should have an initial and thorough endocrinological investigation, as well as a follow-up. 
Due to the higher risk of developing PHD during the first five years of life, the follow-up 
assessments during this period need to be more frequent compared to later in life. Ryabets-
Lienhard et al have recommended evaluations every fourth to sixth months,151 and this seems 
reasonable. In older children, it is important to keep an eye on the timing of puberty and 
evolving central hypothyroidism, and yearly hormonal assessments are probably sufficient. It 
is not known how often PHD evolve during adulthood and consequently, for how long the 
monitoring should continue.  
From a neurological perspective, developmental problems or neurological impairments 
indicate whether the child needs imaging of the brain. Knowledge of major malformations 
and corpus callosum dysgenesis are of prognostic value. Children with motor deficits should 
be further assessed by a physiotherapist and/or an occupational therapist. Patients with 
neurodevelopmental disorders and motor dysfunction should be referred to a habilitation 
center. In addition, all children with ONH should be screened for neurodevelopmental 
disorders before starting school and screening questionnaires, such as the FTF, can be used. If 
developmental problems are detected, further neuropsychological testing should be 
performed. 
Genetic testing is proposed primarily for children with ONH in combination with other 
malformations, neurological dysfunction (especially intellectual disability and ASD), or in 
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cases with related parents and affected siblings. Suggested analyses are array-CGH and 
sequencing of suspected candidate genes, but WGS are useful in priority cases. 
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6 CONCLUSIONS 
The conclusions from this thesis are that the prevalence of ONH in children was 17.3/100 000 
in Stockholm, and unilateral ONH was almost as common as bilateral ONH. 
Children with bilateral ONH have a very high risk of neurodevelopmental disorders, 
especially intellectual disability (56%). Children with unilateral disease have a less 
pronounced risk of intellectual disability (9%), but ASDs were diagnosed in 17% of the 
cohort, without association with laterality of the disease. The high frequency of 
neurodevelopmental disorders in both unilateral and bilateral ONH warrants screening before 
starting school. 
Motor impairments are very common in children with ONH, and more prevalent in bilateral 
disease. Except for neurological evaluation, children with motor deficits should be assessed 
by physiotherapist and occupational therapist for support to improve their motor skills. 
Both children with unilateral and bilateral ONH have a significantly increased risk of 
hypopituitarism (29%). Structural pituitary abnormalities are highly predictive of PHD. 
Accordingly, MRI of the brain including the pituitary gland is of prognostic value. However, 
a normal structural pituitary gland does not rule out hypopituitarism. 
Of the patients with hypopituitarism, 85% were diagnosed with their first PHD diagnosis 
before five years of age. In addition, 79% of all the PHDs were diagnosed within the age of 
five. Subsequently, a more frequent endocrine follow-up is warranted until five years of age 
and thereafter more sparsely until puberty is completed. 
Our results suggest that a genetic cause of ONH is more common than previously reported 
and highlights COL4A1 and COL4A2 as candidate genes. Rare variants in COL4A1 and 
COL4A2 were identified in 6/29 of the patients, and two of the variants were assessed as 
likely pathogenic. We conclude that genetic testing is valuable in a substantial proportion of 
the children with ONH, and in the future, more of these children should be able to receive a 
genetic diagnosis.  
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7 FUTURE PERSPECTIVES 
To understand a disorder, it is important to know what is causing it and how common it is. 
This thesis has underlined the need of population-based cohorts when studying the prevalence 
of ONH, but also associated comorbidities such as neurodevelopmental disorders and 
hypopituitarism. To confirm our results, additional population-based studies are necessary, 
and a future study looking at hypopituitarism should be prospectively designed and include 
clinical assessment of pubertal stages. 
Our research group intends to design a national follow-up program for children with ONH 
based on the studies in this thesis, and this would be a good opportunity to organize a national 
prospective study.  
In study II, we acknowledged the lack of validated testing instruments for ASD in visually 
impaired children. In general, blind children have an increased risk of ASD,87 and in our 
study we could also see that children with ONH received the ASD diagnoses late. This needs 
to be improved to be able to give the children and families early support and a better chance 
for development. Clinically used testing instruments (e.g. ADOS) need to be adjusted for 
visually impaired children and validated. Subsequently, the prevalence of ASD in children 
with both unilateral and bilateral ONH should be reinvestigated. 
The aetiology of ONH is still unknown in most patients. Epidemiological studies are wanted 
to look for risk factors, especially environmental factors that are preventable. Here, 
collaboration between maternity care, ophthalmologist and paediatricians is needed, and 
Swedish registers could be an advantage.  
Genetic causes of ONH should be further studied with WGS, and we plan to analyse all our 
WGS data. This will very likely reveal more pathogenic variants and contribute to the 
understanding of ONH, but also contribute to our understanding of the developing brain. 
Furthermore, the candidate variants need to be confirmed with functional studies, and zebra 
fish could be an interesting model. 
Another way to explore the impact on the brain in children with ONH is to perform diffusion 
tensor imaging and other functional MRI studies. Especially the high prevalence of white 
substance loss could be further investigated with these methods, but also different parts of the 
visual pathway. In fact, we already have ethical approval for this study and patients willing to 
participate. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Optikushypoplasi (optic nerve hypoplasia, ONH) är en medfödd synnervsmissbildning som 
innebär att synnerven är tunn och underutvecklad. ONH kan drabba det ena eller båda ögonen 
och det är en vanlig orsak till synnedsättning och blindhet hos barn i industrialiserade länder. 
Förekomsten av ONH är dock något oklar och tidigare studier har indikerat att förekomsten 
ökar. Ofta drabbas barn med ONH inte bara av synnedsättning, utan de har också en förhöjd 
risk för utvecklingsavvikelser och brist på hypofyshormoner. Dessa hormonbrister kan leda 
till tillväxthämning och kortvuxenhet, pubertetsrubbningar, vätskebalansstörningar, låga 
blodsocker, kramper, ytterligare hjärnskador och i värsta fall dödsfall. Om vi kan finna 
hormonbristen i tid så finns det dock bra behandling att erbjuda.  
Det är vidare oklart hur vanligt det är med intellektuell funktionsnedsättning (tidigare 
benämnt utvecklingsstörning), autism och hormonbrister hos barn med ONH, och det saknas 
ett uppföljningsprogram. Syftet med avhandlingen var att beräkna förekomsten av ONH, 
liksom samsjuklighet med intellektuell funktionsnedsättning, autism, motoriska svårigheter 
och hormonbrister, och därtill jämföra de två grupperna med ensidig eller dubbelsidig ONH. 
Slutligen eftersökte vi genetiska orsaker till ONH eftersom orsaken i de flesta fall är okänd. 
Studie I: I denna studie identifierade vi, via diagnosregister, alla patienter som 
diagnostiserats med ONH och var under 20 år samt boende i Stockholms län i december 
2009. Totalt sett identifierades 79 patienter. Patienterna fick genomgå ögonundersökningar 
för att bekräfta diagnosen och testa synskärpan, dessutom fick föräldrarna fylla i ett ”5-15 
formulär” för bedömning av utveckling och beteende. Denna populationsbaserade 
kohortstudie visade att förekomsten av ONH hos barn i Stockholm var 17.3/100 000. Det är 
den högsta förekomsten som rapporterats internationellt. Sextiosex patienter undersöktes 
klinisk och knappt hälften hade ensidig ONH, vilket är en ovanligt hög andel. 
Utvecklingsavvikelser var vanligare vid dubbelsidig ONH. 
Studie II: Denna studie inkluderade 65 patienter med ONH från ovan beskrivna 
populationsbaserade kohort. Diagnoserna intellektuell funktionsnedsättning och autism 
bekräftades med neurologisk undersökning, genomgång av tidigare neuropsykiatriska 
utredningar och de som inte redan hade utretts erbjöds neuropsykologisk testning. Dessutom 
användes ”5-15 formuläret” för att utesluta intellektuell funktionsnedsättning och autism hos 
dem som inte genomgick någon neuropsykologisk testning men där både neurologisk 
undersökning och skolgång varit normal. Studie II visade att det finns en hög risk för 
intellektuell funktionsnedsättning vid ONH (36%) och att det är vanligare vid dubbelsidig 
ONH (56%) jämfört med ensidig ONH (9%). Patienterna med dubbelsidig ONH hade också 
lägre medelvärde på helskale-intelligenskvot (IQ) än den ensidiga gruppen (84.4 och 99.4, 
respektive). Förekomsten av autism var 17% och skiljde sig inte åt mellan grupperna.  
Studie III: Populationsbaserad kohortstudie med 65 patienter med ONH, varav 46% hade 
ensidig ONH. Patienterna bedömdes med en strukturerad neurologisk undersökning med 
fokus på grov- och finmotorik. De fick också lämna in blodprover för screening av 
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hormonbrister från hypofysen. Utifrån provsvar, bedömning av tillväxtkurvor och tidigare 
sjukdomshistoria fastslogs om patienterna hade brist på hypofyshormon, så kallad 
hypopituitarism. Tidigare datortomografier (skiktröntgen) och magnetkameraundersökningar 
av hjärnan eftergranskades dessutom. I studie III framkom att motoriska svårigheter förekom 
hos 47% av patienterna med ONH och var vanligare vid dubbelsidig ONH och hos dem med 
sämre synskärpa. Cerebral pares (CP) återfanns hos 9% av ONH patienterna och 14% hade 
epilepsi. Brist på hypofyshormon förekom hos 29% av fallen och 19% hade brist på flera 
hypofyshormoner. Vanligast var brist på tillväxthormon (21%). Ett viktigt konstaterande var 
att bristen på hypofyshormon inte var relaterat till ensidig eller dubbelsidig ONH. Dessutom 
såg vi att 85% av dem som fick hypopituitarism hade fått sin första hormonbrist 
diagnostiserad före fem års ålder. Slutligen så fann vi att en strukturellt avvikande hypofys 
hade en stark koppling till hormonbrist. 
Studie IV: Blodprover från 29 patienter med ONH från ovanstående kohort samlades in för 
att på DNA genomföra genetiska analyser med array-CGH, som visar gendosavvikelser i hela 
arvsmassan, och helgenomsekvensering med fokus på 42 kandidatgener. Dessa 42 
kandidatgener har tidigare kopplats till ONH eller närliggande tillstånd. De identifierade 
kandidatvarianterna (mutationerna) bekräftades med Sangersekvensering och föräldraprover 
analyserades för att fastställa nedärvning. Vi fann sällsynta varianter i generna COL4A1 och 
COL4A2 hos sex patienter, varav två varianter bedömdes som sannolikt patogena 
(sjukdomsframkallande). Generna COL4A1 och COL4A2 kodar för två proteiner i kollagen 
typ IV (fiberprotein), som är nödvändigt för basalmembran och är även betydelsefullt vid 
tidig utveckling. Detta fynd talar för att mutationer i COL4A1 och COL4A2 är viktiga 
genetiskt bidragande faktorer vid ONH. Dessutom identifierade vi två andra sannolikt 
patogena varianter i generna SOX5 och PAX6, samt en intressant variant i OPA1. 
Sammantaget talar detta för att genetiska orsaker till ONH är vanligare än vad som tidigare 
rapporterats, men dessa fynd behöver bekräftas med funktionella studier. 
Slutsatser: Förekomsten av ONH hos barn i Stockholm var 17.3/100 000. Ensidig ONH var 
nästan lika vanlig som dubbelsidig. Både barn med ensidig och dubbelsidig ONH har en hög 
risk för neuropsykiatriska sjukdomar och brist på hypofyshormon, men den bilaterala 
gruppen har ännu högre förekomst av intellektuell funktionsnedsättning, motoriska 
svårigheter och hjärnmissbildningar. Våra resultat påtalar ett behov av att barn med ONH 
behöver screenas för neuropsykiatriska sjukdomar senast före skolstart och den hormonella 
uppföljningen behöver vara frekventare de fem första levnadsåren. Vidare indikerar den 
genetiska studien att genetiska orsaker är vanligare än vad som tidigare rapporterats och lyfter 
fram COL4A1 och COL4A2 som intressanta kandidatgener. Sannolikt är genetisk testning av 
värde för en betydande del av barnen med ONH, och med den snabba utvecklingen inom 
genetisk diagnostik så borde fler av dem kunna få en genetisk diagnos i framtiden.
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